Cushion for patient interface

Information

  • Patent Grant
  • 11607515
  • Patent Number
    11,607,515
  • Date Filed
    Thursday, September 19, 2019
    4 years ago
  • Date Issued
    Tuesday, March 21, 2023
    a year ago
Abstract
A cushion for a patient interface that delivers breathable gas to a patient includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. The underlying cushion has a spring-like connection with the base wall. The underlying cushion and/or base wall define a spring constant that varies along a length of the seal.
Description
FIELD OF THE INVENTION

The present invention relates to a cushion for a patient interface, the patient interface being used in the treatment, e.g., of Sleep Disordered Breathing (SDB) with Non-Invasive Positive Pressure Ventilation (NPPV).


BACKGROUND OF THE INVENTION

The use of NPPV for treatment of SDB such as Obstructive Sleep Apnea (OSA) was pioneered by Sullivan (see U.S. Pat. No. 4,944,310). Apparatus for the treatment of SDB involves a blower which delivers a supply of air at positive pressure to a patient interface via a conduit. The patient interface may take several forms, such as a nasal mask assembly and a nasal and mouth mask assembly. Patients typically wear a mask assembly while sleeping to receive the NPPV therapy.


Mask assemblies typically comprise a rigid shell or frame and a soft face-contacting cushion. The cushion spaces the frame away from the patient's face. The frame and cushion define a cavity which receives the nose or nose and mouth. The frame and cushion are held in position on the patient's face by a headgear assembly. The headgear assembly typically comprises an arrangement of straps which pass along both sides of the patient's face to the back or crown of the patient's head.


U.S. Pat. No. 5,243,971 (Sullivan and Bruderer) describes a nasal mask assembly for Continuous Positive Airway Pressure (CPAP) having a ballooning/molding seal that conforms with the patient's nose and facial contours. The mask assembly has a face-contacting portion mounted to a shell which is sized and shaped to overfit the nose region of the patient. The face-contacting portion is in the form of a distendable membrane which is molded from an elastic plastic material. The distendable membrane and the shell together define a chamber. Pressurized gas admitted to the chamber causes the membrane to distend outwardly from the patient's face. The contents of this patent are hereby incorporated by reference.


U.S. Pat. No. 6,112,746 (Kwok et al.) describes a nasal mask assembly and a mask cushion therefor. The contents of this patent are hereby incorporated by reference. The cushion comprises a substantially triangularly-shaped frame from which extends a membrane. The frame has an edge by which the cushion is affixed to a mask body. The membrane has an aperture into which the patient's nose is received. The membrane is spaced away from the rim of the frame, and its outer surface is of substantially the same shape as the rim.


The cushion of a patient interface can play a key role in the comfort and effectiveness of therapy. There is considerable variation in facial size and shape which can mean that a mask designed for one type of face may not be suitable for another. For example, an Asian-type nose tends to have a lower nasal bridge whereas a Caucasian-type nose has a higher nasal bridge. Using the wrong cushion can lead to excessive leak and discomfort. While creating customized cushions for every patient may solve some fitting issues, customized masks are very expensive. Thus, manufacturers seek to develop cushions which provide a comfortable and effective seal for a range of facial sizes and shapes.


SUMMARY OF THE INVENTION

One aspect of the invention is to provide a patient interface having a cushion that provides more comfort to the patient while maintaining an effective seal.


Another aspect of the invention is to provide a comfortable cushion for a patient interface which fits a wide range of facial shapes and sizes.


Another aspect of the invention relates to a cushion including an underlying cushion and a membrane, wherein the underlying cushion and the membrane have a substantially flat portion in a nasal region of the cushion.


Another aspect of the invention relates to a cushion including a base wall, an underlying cushion and a membrane, wherein the base wall and underlying cushion have a cross-sectional configuration that provides a variable spring constant around the perimeter of the cushion.


Another aspect of the invention relates to a patient interface wherein the base wall and the frame connection of the cushion are internally offset with respect to the most external cushion point, e.g., external membrane surface.


Another aspect of the invention relates to a cushion including a base wall and underlying cushion that are inclined or angled in a side of nose region of the cushion.


Another aspect of the invention relates to a cushion having a substantially constant mouth width irrespective of its face height. Another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane includes nasal bridge, cheek, and chin regions adapted to form a continuous seal on nasal bridge, cheek, and chin regions of the patient's face, respectively. The nasal bridge region and adjacent two cheek regions define an intersection or apex. The membrane in the nasal bridge region has a height at the apex or intersection that is greater than a height in an adjacent portion of the cheek region.


Another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. The underlying cushion has a spring-like connection with the base wall. The underlying cushion and/or base wall define a spring constant that varies along a length of the seal.


Another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. One of the membrane and the underlying cushion includes an external surface that defines an outer width of the cushion, and the base wall is internally offset with respect to the external surface.


Yet another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane includes at least nasal bridge and side of nose regions adapted to form a continuous seal on nasal bridge and side of nose regions of the patient's face, respectively. The base wall and the underlying cushion in the side of nose region are inclined or angled with respect to a bottom of the frame.


Yet another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane includes nasal bridge, side of nose, upper cheek, lower cheek and chin regions adapted to form a continuous seal on nasal bridge, side of nose, upper cheek, lower cheek, and chin regions of the patient's face, respectively. An inner edge of the membrane defines an aperture that receives the patient's nose and mouth. A lower portion of the aperture that receives the patient's mouth has a mouth width that remains substantially constant irrespective of a face height of the cushion.


Yet another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. At least a portion of the underlying cushion and/or base wall has a lower portion including a spring configuration that defines displacement of the cushion with respect to a force applied from the frame.


Still another aspect of the invention relates to a method of designing a series of mask assemblies. The method includes providing a first cushion adapted to fit a larger range of patients and providing a second cushion adapted to fit a smaller range of patients. Each of the first and second cushions includes an aperture that receives at least the patient's mouth. The aperture of the first and second cushions have the same width.


Still another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane includes at least a nasal bridge region adapted to form a continuous seal on a nasal bridge region of the patient's face. The membrane forms an elongated ridge in the nasal bridge region. The elongated ridge has sloping sides that meet to form an elongated crest. Each of the sloping sides is angled from a crest centerline in the range of 30-60° and the crest has a radius of curvature in the range of 1.0-5.0 mm.


Still another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane includes at least a nasal bridge region adapted to form a continuous seal on a nasal bridge region of the patient's face. The nasal bridge region of the membrane includes a contoured portion that curves inwardly towards a cavity of the cushion along a radius to terminate at an inner edge of the membrane. The contoured portion has a free end that is angled with respect to a face contacting plane of the cushion in the range of 30-50°.


Still another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. The underlying cushion and/or base wall has a question-mark or sickle shape.


Still another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. The underlying cushion has an arcuate configuration including an arc length greater than 16 mm.


Still another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame, an underlying support cushion extending away from the base wall towards the patient's face in use, and a membrane provided to substantially cover at least a portion of the underlying cushion. The membrane is adapted to form a continuous seal on the patient's face. The membrane includes a thickness that varies along a length of the seal.


Still another aspect of the invention relates to a cushion for a patient interface that delivers breathable gas to a patient. The cushion includes a base wall structured to be connected to a frame and a membrane adapted to form a continuous seal on the patient's face. At least a portion of the base wall includes a tapered portion that tapers towards the membrane.


Still another aspect of the invention relates to a mask system including a set of at least two cushions arranged to suit different face sizes, wherein the at least two cushions have substantially the same width.


Other aspects, features, and advantages of this invention will become apparent from the following detailed description when taken in conjunction with the accompanying drawings, which are a part of this disclosure and which illustrate, by way of example, principles of this invention.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings facilitate an understanding of the various embodiments of this invention. In such drawings:



FIGS. 1-9 illustrate a cushion for a patient interface constructed according to an embodiment of the present invention and showing exemplary dimensions of an embodiment;



FIGS. 10-14 are cross-sectional views through the cushion shown in FIG. 5;



FIG. 15 is a front view of the cushion shown in FIGS. 1-9 that illustrates various regions of the cushion;



FIGS. 16-17 illustrates another size of the cushion shown in FIGS. 1-9;



FIGS. 18-19 illustrates yet another size of the cushion shown in FIGS. 1-9;



FIGS. 20-21 illustrates still another size of the cushion shown in FIGS. 1-9;



FIG. 22 is a cross-sectional view through the cushion shown in FIGS. 1-9 that illustrates parameters that can modify a spring characteristic of the underlying cushion;



FIGS. 23-29 are cross-sectional views through the cushion shown in FIG. 15 and showing exemplary parameters of an embodiment, the cross-sectional views illustrating the underlying cushion only;



FIGS. 30A-30N are cross-sectional views illustrating alternative embodiments of a cushion according to the present invention;



FIG. 31-32 are graphs illustrating the general relationship between Force and Displacement for embodiments of the cushion shown in FIGS. 1-9 and a known cushion commercially sold under the name of UltraMirage® Full Face by ResMed Ltd.;



FIG. 33 is a graph illustrating the general relationship between Force and Displacement for various cross-sections of the cushion shown in FIGS. 23-29;



FIG. 34A illustrates a spring length for the cushion shown in FIGS. 1-9, and showing exemplary dimensions of an embodiment according to the present invention;



FIG. 34B illustrates a spring length for a known cushion commercially sold under the name of UltraMirage® Full Face by ResMed Ltd., and showing exemplary dimensions of the UltraMirage® Full Face;



FIG. 35 is a side view of the cushion shown in FIGS. 1-9;



FIGS. 36-37 are cross-sectional views through the cushion shown in FIG. 35;



FIG. 38 is a front view of the cushion shown in FIGS. 1-9 illustrating a flat portion thereof;



FIG. 38B is a graph illustrating the general relationship between Force and Displacement in a nasal bridge region for embodiments of the cushion shown in FIGS. 1-9 and a known cushion commercially sold under the name of UltraMirage® Full Face mask by ResMed Ltd.;



FIGS. 39-40B are front and cross-sectional views of an embodiment of the cushion shown in FIGS. 1-9, and showing exemplary dimensions of an embodiment according to the present invention;



FIGS. 41-45 are perspective views of an embodiment of the cushion shown in FIGS. 1-9 illustrating the rolling action of the nasal bridge region in use;



FIGS. 46-53 illustrate a known cushion commercially sold under the name of UltraMirage® Full Face by ResMed Ltd.;



FIGS. 54-58 illustrate a cushion for a patient interface according to another embodiment of the present invention and showing exemplary dimensions of an embodiment;



FIGS. 59-63 are cross-sectional views through the cushion shown in FIG. 54;



FIG. 64 is a cross-sectional view of a portion of the cushion shown in FIGS. 54-58 (in solid lines) overlaid with a cross-section of a known cushion commercially sold under the name of UltraMirage® Full Face by ResMed Ltd. (only relevant portions of the UltraMirage® cushion may be shown in dashed lines, i.e., there may be other different portions not shown);



FIG. 65 is a cross-sectional view of a portion of the cushion shown in FIGS. 54-58 showing exemplary dimensions of an embodiment according to the present invention;



FIGS. 66-69 are cross-sectional views through the cushion shown in FIG. 54, and showing exemplary dimensions of an embodiment according to the present invention;



FIGS. 70-71 are plan and cross-sectional views, respectively, of the cushion shown in FIG. 54, and showing exemplary dimensions of an embodiment according to the present invention;



FIGS. 72-76 illustrate a cushion for a patient interface according to another embodiment of the present invention;



FIGS. 77-83 illustrate a cushion for a patient interface according to another embodiment of the present invention;



FIGS. 84-90 illustrate a cushion for a patient interface according to another embodiment of the present invention;



FIG. 91 illustrates an alternative cushion cross-section to that shown in FIG. 34A;



FIG. 92 illustrates another alternative cushion cross-section to that shown in FIG. 34A;



FIG. 93 illustrates an alternative cushion arrangement to that shown in FIG. 15;



FIGS. 94A-94C are a set of views depicting a horizontal cross-section through the nasal bridge region of the cushion of FIG. 35; and



FIGS. 95A-95C are a set of views depicting a horizontal cross-section through the nasal bridge region of the prior art cushion of FIG. 51.





DETAILED DESCRIPTION OF ILLUSTRATED EMBODIMENTS


FIGS. 1-14 illustrate a cushion 10 constructed according to an embodiment of the present invention. The cushion 10 is adapted to be removably or permanently connected (e.g., via mechanical and/or adhesive fastening) to a frame of a patient interface structured to deliver breathable gas to a patient. In an embodiment, the cushion 10 may be co-molded to a frame of a patient interface. In another embodiment, the cushion may form part of a frame with an outer support structure, e.g., ResMed's Hospital Nasal Mask. The cushion 10 provides a seal with the patient's face during use.


In the illustrated embodiment, the cushion 10 forms a part of a full-face mask. Specifically, the cushion 10 provides a seal around the patient's nose and mouth to enable the delivery of breathable gas to the patient's nose and mouth. However, aspects of the present invention may be applicable to other breathing arrangements, e.g., a nasal mask, a mouth mask, etc. The cushion 10 may be used with a gusset as described in U.S. patent application Ser. No. 10/655,622, incorporated herein by reference in its entirety.


The cushion 10 is structured to provide a more comfortable fit for a wide range of facial shapes and sizes. Also, the cushion 10 is structured to provide a better seal and reduce the risk of leakage as discussed below.


As illustrated in FIGS. 1-14, the cushion 10 includes a non-face-contacting portion 12 structured to be connected to a frame of the patient interface, e.g., via a friction-fit, a tongue-and-groove arrangement, etc., and a face-contacting portion 14 structured to engage the patient's face.


As best shown in FIGS. 5 and 15, the face-contacting portion 14 of the cushion 10 preferably has a generally triangular shape and is structured to continuously contact nasal bridge, side of nose, upper cheek, lower cheek, and chin regions of the patient. However, the face-contacting portion 14 may have other suitable shapes, e.g., a generally trapezoidal shape. In the illustrated embodiment, as best shown in FIG. 15, the cushion 10 includes a nasal bridge region 16 to provide a seal along the patient's nasal bridge, a pair of cheek regions 15 to provide a seal along the patient's nose, cheek, and mouth, and a chin region 20 to provide a seal along the patient's chin. The pair of cheek regions 15 may be further defined as a pair of side of nose regions 17 to provide a seal along the sides of the patient's nose, a pair of upper cheek regions 18 to provide a seal along upper cheeks of the patient, and a pair of lower cheek regions 19 to provide a seal along the patient's lower cheeks and the sides of the patient's mouth.


Width of Cushion in Lower Cheek Regions and Ratio of Face Width to Height Across Mask Sizes


The cushion 10 may be provided in various sizes in order to accommodate various facial sizes. For example, FIGS. 16-21 illustrate embodiments of the cushion 10 in three other sizes. In an embodiment, the cushion 210 shown in FIGS. 16-17 may represent a extra small size, the cushion 310 shown in FIGS. 18-19 may represent a small size, the cushion 10 shown in FIGS. 1-14 may represent a medium size, and the cushion 410 shown in FIGS. 20-21 may represent a large size. As illustrated, the mouth widths w3, w1, w2 and w4 of the cushions 10, 210, 310, 410 are substantially constant irrespective of their face heights h3, h1, h2 and h4.


Specifically, the cushion 10 defines an aperture 22 that receives the patient's mouth. In a preferred embodiment, the lower portion of the aperture 22 has a constant width for all cushion sizes, e.g., 60 mm. However, the width of the lower portion of the aperture 22 may be almost constant, e.g., in a range of 5 mm, for all cushion sizes. For example, the width of the lower portion of the aperture 22 of the cushion 10 may be 60 mm±5. In contrast, the width of the lower portion of the aperture 722 of a known cushion 700 commercially sold under the name of UltraMirage® Full Face by ResMed Ltd. is 60 mm for a large size, 54 mm for a medium size, and 52 mm for a small size. The UltraMirage® cushion 700 is shown in FIGS. 46-53.


Anthropometric data has indicated that mouth widths for patients with relatively small faces are not necessarily narrower than mouth widths for patients with relatively large faces. Hence, all faces generally have the same mouth width. Thus, the aperture 22 in the cushion 10 is made sufficiently wide to accommodate a wide range of patients and remains constant or almost constant, e.g., a range of 5 mm, regardless of the change in face height of a mask to fit larger faces. This can be seen in the substantially constant cushion geometry around the lower cheek and chin regions of the different cushion sizes, and thus the varying width to height ratios of the different cushion sizes. For example, the lower portion of the aperture 22 of each of the cushions 10, 210, 310, 410 has substantially the same width.


Base Wall, Underlying Cushions, and Membrane


As best shown in FIGS. 9 and 10-14, the face-contacting portion 14 of the cushion 10 includes a base wall 28, a pair of underlying support cushions 30 extending away from the base wall 28, and a membrane 32 provided to substantially cover at least a portion of the underlying cushions 30 and provide a sealing structure for the face contacting portion 14. The base wall 28 and underlying cushions 30 provide a support structure for the membrane 32.


As illustrated, the underlying cushions 30 are preferably provided on lateral sides of the base wall 28 only, e.g., in the side of nose, upper cheek, and lower cheek regions 17, 18, 19, although the underlying cushions 30 could be joined and substantially surround the patient's nose and also the lower lip or chin region. The underlying cushions 30 add rigidity to the membrane 32 at the sides of the patient's mouth and cheeks. While it is preferable that the membrane 32 be thinner than the underlying cushions 30, they could have the same thickness or the membrane could be thicker than the underlying cushion. Also, the elimination of an underlying cushion in the chin region 20 allows the cushion 10 to more deeply engage with the patient's face in this region without subjecting the patient's chin region 20 to excessive pressure. That is, there is no underlying cushion to restrain the movement of the membrane 32 in this region, which may improve the seal in this region and adjacent regions. Additionally, the elimination of an underlying cushion in the chin region 20 enables the cushion 10 to accommodate more facial shapes and provides more flexibility and allows for movement or opening of the mouth.


In the illustrated embodiment, the face-contacting portion 14 of the cushion has a double-walled construction, i.e., membrane 32 and underlying cushion 30, in the side of nose, upper cheek, and lower cheek regions 17, 18, 19, and a single-walled construction, i.e., membrane 32, in the nasal bridge and chin regions 16, 20 as shown in FIGS. 10-14. The single wall construction at the top and bottom of the cushion 10 helps to accommodate high landmarks, e.g., pointed chin, by allowing the center of the cushion 10 to flex. This flexibility accommodates more patients with the same cushion. However, the cushion 10 may have any other suitable construction, e.g., single walled, double walled, triple walled or more walled construction, in any suitable region of the cushion 10, e.g., cheek, chin, nasal bridge. For example, the underlying cushion 30 may extend around the entire perimeter of the cushion 10. Also, the underlying cushion 30 could be completely removed.


As shown in FIGS. 10-14, the membrane thickness may vary in the different regions of the cushion 10. As illustrated, the membrane in the nasal bridge region 16 and upper cheek region 18 is 0.3 mm thick which transitions to 0.5 mm thickness in the upper cheek region 18 and maintains this thickness in the lower cheek and chin regions 19, 20. This arrangement provides greater compliance/stretch across the nasal bridge by providing a thinner membrane. This stretch is not required at the lower regions and here the thicker membrane is less likely to vibrate on the patient face in use.


Internally Offset Base Wall and Frame Connection


Another aspect of the invention relates to the size and configuration of the base wall 28, underlying cushion 30, and membrane 32 of the cushion 10. FIGS. 48-50 illustrate the base wall 728, underlying cushion 730, and membrane 732 of the UltraMirage® cushion 700. As illustrated, the cushion 10 has a different cross-sectional profile than the UltraMirage® cushion 700.


For example, as best shown in FIGS. 11-13, the base wall 28 and the frame connection 29 are internally offset with respect to the most external cushion point 39, e.g., external surface of membrane or underlying cushion. In contrast, the base wall 728 and frame connection 729 of the UltraMirage® cushion 700 are not offset with respect to the most external cushion point 739 (see FIGS. 48-50). As a result of this inward movement, the base width of the cushion 10 is narrowed, e.g., by about 5 mm or 2.5 mm per base, which provides a less obtrusive cushion and saves material which means less weight and cost. Also, the narrower cushion 10 provides less free length for the cushion 10 to bulge outwardly in use, thus helping to minimize or eliminate leakage.


As illustrated, a lower portion of the underlying cushion 30 has a more arcuate, e.g., semi-circular, question-mark, sickle-shape, configuration that defines a space 34 below a lower portion of the underlying cushion 30 and adjacent the base wall 28.


In the illustrated embodiment, the widest or most external cushion point is the external surface of the underlying cushion 30 and the base wall 28 and frame attachment 29 are offset internally with respect to this. Thus, by the design of the cushion 10 and in particular the underlying cushion curvature, the frame is attached at a narrower point and thus the frame itself is narrower. This arrangement has significant advantages in terms of the frame weight, perceived bulk, and size. This arrangement may also minimize the dead space within the mask which will help to reduce CO2 rebreathing.


Moreover, the space 34 below the underlying cushion 30 allows a greater range of movement of the underlying cushion 30 to add more flexibility to the underlying cushion 30 and hence the membrane 32 in use. Specifically, the space 34 below the underlying cushion 30 enables more displacement of the underlying cushion 30 using substantially the same space restraints as the UltraMirage® cushion 700, for example. Additionally, the space 34 allows more displacement of the underlying cushion 30 before bottoming out, therefore reducing discomfort. Thus, this arrangement provides a more gradual force, improves comfort, and allows a wider range of patients to achieve seal.


Variable Spring Constant


As illustrated, the underlying cushion 30 has a spring-like connection with the base wall 28 such that the underlying cushion 30 can move with respect to the base wall 28. That is, the underlying cushion 30 is movable into the space 34 (the underlying cushion 30 is also movable into the space 33). Thus, a spring force is provided when a frame force is applied and the underlying cushion 30 is resiliently moved back into its initial position when the frame force is released. The underlying cushion 30 and/or base wall 28 may have any suitable spring constant, and the spring constant may be varied anywhere along its length, e.g., by tapering and/or varying the thickness of the base wall 28, varying the thickness of intermediate and/or lower portions of the underlying cushion 30. Also, the spring-like connection may extend along the whole underlying cushion 30 or the spring-like connection may be localized in certain regions such as the cheekbone region.


Thus, a spring characteristic is molded with the base wall 28 and underlying cushion 30 of the cushion 10 which allows a continuously variable spring constant to be incorporated into the base wall 28 and underlying cushion 30, e.g., the wall stiffness can be varied at each cushion region to suit the sealing requirements in each region which may vary due to the underlying facial structure of the patient.


The spring characteristics of the base wall 28 and underlying cushion 30 may be modified by varying a number of characteristics shown in FIG. 22. For example, the spring characteristics may be modified by varying the underlying cushion height h, the thickness t, the radius r, and the underlying cushion offset c. It is to be understood that these parameters are merely exemplary, and other parameters may be varied to modify the spring characteristics of the base wall 28 and underlying cushion 30.



FIGS. 23-29 illustrate parameters of an embodiment of the underlying cushion 30 and base wall 28 to achieve desired spring characteristics. As illustrated, the underlying cushion 30 and base wall 28 is configured to provide a variable spring constant around the perimeter of the cushion 10. That is, the spring constant of the underlying cushion 30 and base wall 28 differs along the side of nose, upper cheek, and lower cheek regions 17, 18, 19. Although specific parameters of the cushion 10 are shown in FIGS. 23-29, it is to be understood that these parameters are merely exemplary and other parameters are possible depending on application.


In the nasal bridge region 16 (e.g., see FIG. 10), no underlying cushion 30 is provided in order to provide high flexibility and the ability to conform to a variety of facial shapes. However, in an embodiment, there may be an underlying cushion 30 with a very soft spring characteristic in this region.


In the side of nose regions 17 (see FIGS. 23-24), an underlying cushion 30 and base wall 28 with a fairly stiff spring characteristic is provided in order to provide lateral stability to squeeze the side of the patient's nose and keep the membrane 32 in contact with the underlying cushion 30. As illustrated, this arrangement is achieved by a relatively thick underlying cushion, short height, and tight radius. In an embodiment of the section shown in FIG. 23, h may be 12 mm, r may be 5 mm, t may be 2-3 mm, b may be 4 mm, w1 may be 11.5 mm, and w2 may be 8 mm. In an embodiment of the section shown in FIG. 24, h may be 14 mm, r may be 6-7 mm, t may be 2.5 mm, b may be 4 mm, w1 may be 11.5 mm, w2 may be 9.5 mm, and α may be 22°. It is to be understood that these dimensions and ranges are merely exemplary and other dimensions and ranges are possible depending on application.


Also, as best shown in FIG. 24, the base wall 28 and underlying cushion 30 in the side of nose regions 17 have been rotated by about 22 degrees with respect to the bottom of the frame. That is, the base wall 28 and underlying cushion 30 are inclined or angled in the side of nose regions 17 of the cushion 10. This arrangement further increases the lateral stability and allows the force on the membrane to be applied perpendicular to the skin surface at the side of the patient's nose. This further helps to keep the membrane 32 in contact with the patient's skin and prevent any air leaks. In further embodiments, this angle may vary from 15 to 30 degrees.


In the upper cheek regions 18 (see FIGS. 25-26), the underlying cushion 30 and base wall 28 have a stiffness that is less than that provided in the side of nose regions 17 but stiffer than that provided in the lower cheek regions 19 due to the geometry of the underlying cushion, this is provided to suit the firmer bone structure of the upper cheeks. In an embodiment of the section shown in FIG. 25, h may be 12-15 mm, preferably 13.5 mm, r may be 5 mm, t may be 2 mm, b may be 3 mm, and w1 may be 11.5 mm. In an embodiment of the section shown in FIG. 26, h may be 12-15 mm, preferably 13.5 mm, r may be 5 mm, t may be 2 mm, b may be 3 mm, and w1 may be 11.5 mm. It is to be understood that these dimensions and ranges are merely exemplary and other dimensions and ranges are possible depending on application.


In the lower cheek regions 19 (see FIGS. 27-29), the underlying cushion 30 and base wall 28 has a relatively low spring constant. That is, the underlying cushion 30 in the lower cheek regions 19 is fairly soft since the fleshy cheek region of the patient deforms readily to form a seal with the cushion at relatively low forces. As illustrated, this arrangement is achieved by a greater height h, larger radii r, and a thinner underlying cushion wall. In an embodiment of the section shown in FIG. 27, h may be 14 mm, r1 may be 5 mm, r2 may be 7 mm, t may be 1.5-2 mm, b may be 3.5 mm, and w1 may be 11.5 mm. In an embodiment of the section shown in FIG. 28, h may be 16.5 mm, r1 may be 6-7 mm, r2 may be 8 mm, t may be 1.5 mm, b may be 3.5 mm, and w1 may be 11.5 mm. In an embodiment of the section shown in FIG. 29, h may be 17.5 mm, r1 may be 6-7 mm, r2 may be 9-10 mm, t may be 1.5 mm, b may be 3.5 mm, and w1 may be 11.5 mm. It is to be understood that these dimensions and ranges are merely exemplary and other dimensions and ranges are possible depending on application.


In the chin region 20 (see FIG. 14), no underlying cushion 30 is provided, although a very flexible spring region may be used. The chin region 20 provides an unconstrained membrane region that allows for lateral movement, mouth opening or movement, and a range of facial shapes.


Thus, the cushion 10 may be configured to provide different vertical and/or lateral stiffness in different regions of the cushion. For example, the side of nose regions 16, 17 are laterally stiffer than the other regions in order to provide more lateral stability at the patient's nose.


Alternative Embodiments of Base Wall and Underlying Cushion



FIGS. 30A-30N illustrate alternative embodiments of the base wall 28 and the underlying cushion 30. Each of these embodiments provides an arrangement that allows flexibility of the underlying cushion 30 in use. In FIG. 30A, the underlying cushion 30 defines an enclosed space 60 that may optionally be filled with pressurized air, foam, gel, or elastomeric material and adapted to dampen movement of the underlying cushion 30 in use. In FIG. 30B, the space 34 below the underlying cushion 30 is within the interior of the breathing cavity. Also, the underlying cushion 30 has an arcuate shape that curves away from the interior of the breathing cavity towards the base wall 28. However, the underlying cushion 30 may have any other suitable shape. For example, the underlying cushion 30 in FIG. 30C has a bulbous shape, which may be solid or hollow. In FIG. 30D, the underlying cushion 30 has a general Z-shape. In FIGS. 30E and 30F, the underlying cushion 30 has a bulbous shape (which may be solid or hollow), and the space 34 below the underlying cushion 30 has a ramped configuration. In FIGS. 30C, 30E, and 30F, the bulbous shape may optionally be filled with pressurized air, foam gel, or elastomeric material and adapted to dampen movement of the underlying cushion 30 in use. In FIG. 30E the ramped configuration of the space 34 is adapted to direct the underlying cushion 30 downwardly into the base wall 28 in use, and in FIG. 30F the ramped configuration of the space 34 is adapted to direct the underlying cushion 30 inwardly towards the breathing cavity in use. In FIGS. 30G, 30H, and 30I, the underlying cushion 30 has a general T-shape. Also, in FIGS. 30H and 30I, the base wall 28 defines an enclosed space 62 below the T-shaped underlying cushion 30. The enclosed space 62 may be optionally filled with pressurized air, foam, gel, or elastomeric material and adapted to dampen movement of the underlying cushion 30 in use. Moreover, the spring constant may be varied by varying the pressure within the enclosed space 62. Additionally, the lower surface of the space 62 may have a ramped configuration (as shown in FIG. 30H) adapted to direct the underlying cushion 30 inwardly towards the breathing cavity in use. The lower surface of the enclosed space 60 in FIG. 30A may also have a ramped configuration for directing the underlying cushion 30 in use. In FIGS. 30J and 30K, the underlying cushion 30 has an elongated section length for soft spring characteristics. FIG. 30L illustrates a single wall construction with an underlying cushion 30 and no membrane. In FIG. 30M, the space 34 below the underlying cushion 30 is greatly increased. In FIG. 30N, a spring construction is provided below the base wall 28.


Displacement Provided by Underlying Cushion


The space 34 allows more displacement of the underlying cushion 30 for a predetermined amount of force when compared to the UltraMirage® cushion 700. That is, the underlying cushion 30 provides more movement for a given force. For example, FIG. 31 illustrates the general relationship between Force and Displacement for the cushion 10 and the UltraMirage® cushion 700. As illustrated, the curve for the cushion 10 is flatter than the exponential-type curve of the UltraMirage® cushion 700. Thus, the underlying cushion 30 is less stiff and more compliant when compared to the UltraMirage® cushion 700. It is noted that the space 34 could be filled with a gel, silicone or other structure to vary the spring characteristic that it provides.


Further, as illustrated in FIG. 31, the point B10 at which the cushion 10 is fully compressed or bottomed-out is at a greater displacement than the point B700 at which the UltraMirage® cushion 700 is bottomed-out. Moreover, the bottom-out point B10 occurs at a greater force than the bottom-out point B700. Thus, the cushion 10 increases the force required to bottom-out, and provides a wider range of adjustment. Additionally, FIG. 31 illustrates an example of maximum and minimum comfortable sealing forces, which provides an example force range necessary to achieve seal. As illustrated, the range of displacement A10 within this force range for the cushion 10 is substantially larger than the range of displacement A700 within this force range for the UltraMirage® cushion 700. Thus, the cushion 10 allows a wide range of adjustment or displacement to achieve seal, and ensures that the sealing force is substantially less than the bottom-out force so that the cushion does not have to bottom-out to seal.



FIG. 32 illustrates another embodiment of the relationship between Force and Displacement for the cushion 10 and the UltraMirage® cushion 700. In this embodiment, the linear portion of the curve for cushion 10 has a greater slope than the linear portion of the curve for cushion 10 in FIG. 31. The difference in slope may be attributed to a difference in spring constants of respective underlying cushions 30. Thus, the cushion represented in FIG. 31 provides more displacement for a given force than the cushion represented in FIG. 32. Also, the curve for the cushion 10 in FIG. 32 intersects with the curve for the UltraMirage® cushion 700, such that the force of cushion 10 is higher at lower displacement, to ensure a seal, and lower at higher displacement, to maintain comfort for a longer range of displacement.



FIG. 33 illustrates another embodiment of the relationship between Force and Displacement for the cushion 10. In this embodiment, typical curves for the different regions of the cushion 10 are shown. Specifically, one curve represents the cross-sections of FIGS. 23-24 in the side of nose region 17, another curve represents the cross-sections of FIGS. 25-27 in upper cheek and lower cheek regions 18, 19, and yet another curve represents the cross-sections of FIGS. 28-29 in the lower cheek region 19. As illustrated, the cushion 10 is softer or less stiff in the lower regions of the cushion 10.


Extended Spring Length of Underlying Cushion



FIGS. 34A and 34B illustrate the extended length of the flexible underlying cushion 30 which is used to provide a softer spring characteristic in selected regions of the cushion 10 when compared with a typical prior art cushion, e.g., the UltraMirage® cushion 700. The length a to b can deform, thus providing a spring characteristic. As illustrated, the length a to b of the cushion 10 (FIG. 34A) is considerably longer when compared to the UltraMirage® cushion 700 (FIG. 34B) due to the curvature of the underlying cushion 30. In the illustrated embodiment, the length a to b of the cushion 10 is 22.84. However, in an embodiment, the length a to b of the cushion 10 may be in the range of 16-30, preferably 20-25, most preferably 22-24. In another embodiment, the length a to b of the cushion 10 may be in the range of 16-20. The length b to c is fairly rigid and does not deform to provide a spring characteristic. The added length in the cushion 10 has been achieved by the arcuate shape of the underlying cushion 30 and the space 34 is a result of this shape. This added length adds flexibility and a greater range of movement to the cushion 10. FIGS. 30J and 30K illustrate other embodiments for achieving a longer section length.


Configuration of Membrane in Nasal Bridge Region


The membrane 32 is structured to form an effective seal around nasal bridge, side of nose, upper cheek, lower cheek, and chin regions 16, 17, 18, 19, 20 of a patient. Another aspect of the invention relates to the configuration of the membrane 32 in the nasal bridge region 16 of the cushion 10, which has been structured to improve sealing and comfort in this region.


Specifically, as shown in a preferred embodiment in FIG. 36 and in an alternative embodiment in FIG. 68, the membrane 32 forms an elongated ridge 35 in the nasal bridge region 16 wherein sloping sides 36 meet to form an elongated crest 38. Each of the sloping sides 36 is angled from the crest centerline in the range of 30-60°, preferably about 47°. The crest 38 has a radius of curvature in the range of 1.0-5.0 mm, preferably about 2.5 mm. As illustrated, the underlying cushion 30 has been eliminated from beneath the membrane 32 in the nasal bridge region 16, which allows the membrane 32 in this region to freely move between the underlying cushions 30 provided in the side of nose regions 17. As discussed in greater detail below, this membrane configuration allows the creation of a steeply inverted section upon engagement with the patient's nose, which improves fit, comfort, and seal in the nasal bridge region 16. In contrast, the UltraMirage® cushion 700 is relatively flat in this region (see FIG. 52).


As shown in a preferred embodiment in FIG. 37 and in an alternative embodiment in FIG. 69, the forward end 40 of the elongated ridge 35 has an arcuate configuration. The forward end 40 is structured to engage the patient's nasal bridge region and has a radius of curvature in the range of 1.5-7.0 mm, preferably about 4.0 mm.


Sharp Cross-Sectional Profile of Nasal Bridge Region


As shown in FIG. 10, the membrane 32 in the nasal bridge region 16 has a sharper cross-sectional profile than the corresponding portion of the UltraMirage® cushion 700 (see FIG. 48). Specifically, the membrane 32 provides a large contoured portion that curves inwardly towards the cavity of the cushion along a radius to terminate at an inner edge of the membrane 32. This arrangement more closely follows the contour or curvature of the patient's nasal bridge region. In the illustrated embodiment, the membrane 32 is angled with respect to a face contacting plane of the cushion, e.g., in the range of 30-50°. In contrast, the corresponding angle of the UltraMirage® cushion 700 is about 6°. This arrangement provides more comfort and a better fit for the patient.


Flat Portion in Nasal Bridge Region


As best shown in FIG. 38, the nasal bridge region 16 has a substantially flat portion 50, e.g., on the apex of the membrane curvature, in elevation view that may deform to provide a more comfortable fit for a wide range of patients, e.g., from flatter nasal bridges to sharper nasal bridges.


Specifically, one aspect of the invention is to provide a membrane 32 in the nasal bridge region 16 that will accommodate “flat faces”, e.g., those patient's with a low nasal bridge. In order to achieve this, the cushion 10 has an upper point A which is higher than or level with points B (see FIG. 38). This height in the nasal bridge region 16 is combined with a rolled edge that keeps the surface area of the membrane 36 substantially flat against the patient's nasal bridge. Keeping the surface area of the membrane 36 substantially flat against the patient's nasal bridge prevents leaks at the edge of the membrane.


The rolled edge also allows movement to accommodate higher nasal bridges. This arrangement is achieved without “stretching” the membrane which can lead to discomfort and patient sores. For example, the displacement of the cushion 10 at the nasal bridge region 16 may be greater than about 40 mm, e.g., 41 mm. In contrast, the UltraMirage® cushion 700 provides displacement of about 20 mm in the nasal bridge region. At these displacements, the membrane becomes quite taut, i.e., the point on the force vs. displacement graph where the force begins to rise sharply for a small displacement (see FIG. 38B).


The displacement values of the cushion in the nasal bridge region for some prior art cushions are as follows:


ResMed™ Activa® Nasal Cushion—16 mm


Respironics Comfort Full Face Cushion—26 mm


ResMed Bubble Nasal Mask Cushion—43 mm


Healthdyne Soft Series Nasal Mask Cushion—17 mm


The above displacement values are by no means an accurate representation of what nose depth the cushion will cover. Rather, these displacement values are only an indication of the flexibility and/or range of the membrane. Thus, the cushion 10 provides an arrangement that is much more flexible and/or rangy than the UltraMirage® cushion 700, for example.


The force vs. displacement graph of membrane 32 in the nasal bridge region 16 has a large displacement for relatively low forces. For example, as shown in FIG. 38B, the displacement provided by the cushion 10 in the nasal bridge region 16 is larger than that provided by the UltraMirage® cushion 700. This allows the cushion 10 to accommodate relatively deep nasal bridges in use. Also, the molded (undeformed) cushion state of the UltraMirage® cushion 700 (i.e., no force applied) does not comfortably accommodate a relatively flat or shallow nasal bridge. In an embodiment, the membrane of the cushion 700 blows out to meet patient's faces with shallow nasal bridges. Thus, the cushion 10 also accommodates a wider range of nasal bridge shapes than the UltraMirage® cushion 700.


Further, as shown in FIG. 36, the profile of the membrane is more sharply peaked as compared to a flat profile or a saddle shape (e.g., compare with UltraMirage® cushion 700 in FIG. 52). Also, as shown in FIG. 35, flat portion in the nasal bridge region 16 extends along a relatively flat plane P1, and this plane P1 is angled at an angle A with respect to the plane P2 that defines the frame connection.


Thus, the shape (e.g., peak), the rolled edge, and the height, in the nasal bridge region 16 provide large displacement at relatively low forces. This arrangement accommodates a wider range of patients, e.g., from those with a low nasal bridge to those with a high nasal bridge, while maintaining a seal against the patient's face with little force on the membrane.


It is noted that the cushion height may vary around the cushion perimeter to vary flexibility or cushion displacement in different regions of the cushion. A reference dimension 940 for measurement of the cushion height (which may also be referred to as the membrane height)—i.e. the height between the apex of the membrane to where it meets the underlying cushion—is shown in FIG. 94C. A reference dimension 950 for measurement of the cushion height of the prior art cushion is shown in FIG. 95C.


Aperture in Membrane


As shown in FIGS. 39-40B, the inner edge of the membrane 32 defines the aperture 22 that receives the patient's nose and mouth. As illustrated, the aperture 22 has a generally triangular shape. Also, the apex of the aperture 22 has a rounded notch 42, e.g., keyhole. The notch 42 improves the seal with nasal bridge regions of various sizes and shapes, particularly patients with sharp noses. The notch 42 has a radius of curvature in the range of 1.5-6.0 mm, preferably about 3.0 mm. This rounded keyhole shape has a length, e.g., the keyhole shape extends outwards from an interior portion of the cushion, of at least 3.0 mm, as shown in FIG. 40A.


Rolling Action of Nasal Bridge Region of Cushion in Use



FIGS. 41-45 include hand-marked lines applied to the outer surface of the nasal bridge region 16 of the cushion 10 to illustrate the rolling action of the nasal bridge region 16 of the membrane 32 upon engagement with the patient's nose. As described above, the membrane 32 in the nasal bridge region 16 includes sloping sides 36 that meet to form an elongated crest 38 as shown in FIG. 41. As the patient's nasal bridge (simulated using a small rod) is engaged with the nasal bridge region 16 of the membrane 32 (see FIG. 42), the membrane 32 creates a steeply inverted section 44 wherein the sloping sides 36 invert their position as the membrane 32 moves between the underlying cushions 30 provided in the side of nose regions 17. As the membrane 32 comes more into contact with the patient's nasal bridge, the leading edge 46 of the inverted section “rolls” towards the top of the cushion 10 as the membrane 32 conforms to the patient's face as shown in FIG. 43. This structure is advantageous since it allows the cushion 10 to accommodate patients having a wide range of nasal profiles, including those with relatively low and relatively high root depth at the nose. FIGS. 44 and 45 show the nasal bridge region 16 of the membrane 32 in its completely inverted position. The creation of the steeply inverted section 44 upon engagement with the patient's nose provides a better seal and reduces the risk of creasing and/or folding and associated discomfort and leaks. That is, this configuration encourages rolling instead of creasing which can be detrimental to patient comfort and seal.


Alternative Embodiments



FIGS. 54-71 illustrate another embodiment of a cushion 510. In each of the figures, portions of the cushion 510 that are substantially similar to the cushion 10 are indicated with similar reference numerals.



FIG. 64 illustrates the base wall 528, underlying cushion 530, and membrane 532 of the cushion 510 (in solid lines) in relation to the base wall 728, underlying cushion 730, and membrane 732 of the UltraMirage® Full Face cushion 700 (in dashed lines). As illustrated, the cushion 510 has a different cross-sectional profile than the UltraMirage® Full Face cushion 700.


For example, the membrane 532 is connected to the underlying cushion 530 at a position that is further inwardly and upwardly with respect to the membrane connection of the UltraMirage® cushion 700. This arrangement substantially removes the vertically extending groove 731 provided in the UltraMirage® cushion 700. Also, this arrangement narrows the width of the membrane 532, e.g., in the range of 0-5, preferably about 2.5 mm, with respect to the corresponding portion of the UltraMirage® cushion 700. As a result of this and the inward movement of the non-face contacting portion 512, this narrows the total width of the cushion 510 by about 5 mm, e.g., about 2.5 mm per base, which provides a less obtrusive cushion and saves material. Also, the narrower membrane 532 provides less free length for the cushion 510 to bulge outwardly in use, thus helping to minimize or eliminate leakage. Further, the base wall 528 and the frame connection 529 are internally offset with respect to the most external cushion point, e.g., external surface of underlying cushion. FIG. 64 also shows the longer length a to b in the cushion 510 when compared to the UltraMirage® cushion 700.



FIG. 65 illustrates further structural details and dimensions in one embodiment of the base wall 528, underlying cushion 530, and membrane 532 of the cushion 510. For example, the depth of the space 534 is in the range of 0-4.0 mm, preferably about 3.0 mm.



FIG. 68 illustrates the elongated ridge 535 in the nasal bridge region 516. Each of the sloping sides 536 is angled from the crest centerline in the range of 30-60°, preferably about 47°. The crest 538 has a radius of curvature in the range of 1.0-5.0 mm, preferably about 2.5 mm. As shown in FIG. 69, the forward end 540 of the elongated ridge 535 has a radius of curvature in the range of 1.5-7.0 mm, preferably about 4.0 mm.



FIGS. 70 and 71 illustrate the flat portion 550 in the nasal bridge region 516 of the cushion 510. Also, as shown in FIG. 71, the membrane 532 in the nasal bridge region 516 has a first portion with a radius of curvature in the range of 50-80 mm, preferably about 65 mm, and a second portion with a radius of curvature in the range of 5.5-9.5 mm, preferably about 7.5 mm. In the illustrated embodiment, the membrane 532 is angled with respect to a face contacting plane of the cushion in the range of 30-50°, preferably about 40°.



FIGS. 72-76 illustrate another embodiment of a cushion 610. As best shown in FIG. 76, the cushion includes at least a base wall 628 and a membrane 632. As illustrated, the length of the membrane 632 (e.g., membrane cross-sectional length) in a nasal bridge region may change. For example, the membrane length may be selected to have a shorter length L1 or a longer length L2 in the nasal bridge region.


As shown in FIGS. 74 and 75, the membrane length controls how far on the patient's nose the displaced cushion membrane will sit when fitted onto the patient's face (shown by the dotted line on the patient's facial profile). This arrangement prevents the potential (e.g., particularly for patients with a shallow nasal bridge depth) for any excess cushion membrane to sit too far down on the patient's nose, which may lead to facial discomfort and skin markings on the patient's nose.



FIGS. 77-83 illustrate another embodiment of a cushion 810. The cushion 810 includes a base wall 828, an underlying support cushion 830, and a membrane 832. As described above, the underlying cushion 830 is preferably provided on lateral sides of the cushion 810 only.


The base wall 828 may be internally offset with respect to the most external cushion point, e.g., external surface of membrane or underlying cushion. This arrangement provides a spring characteristic which may be varied around the cushion perimeter to vary the cushion flexibility (lateral and/or vertical) around the cushion perimeter, e.g., the cushion stiffness can be varied at each cushion region to suit the sealing requirements in each region which may vary due to the underlying facial structure of the patient. That is, the level if bias (e.g., from “hard” to “soft”) along the sides of the cushion may be changed.


For example, FIGS. 77-83 illustrate cross-sections through three different regions R1, R2, R3 in the cushion 810. As shown in FIG. 81, the base wall 828, the underlying cushion 830, and the membrane 832 cooperate to define a relatively straight external surface 880. This provides a minimal spring component in the region R1, e.g., hard or stiff characteristics.


As shown in FIG. 82, the base wall 828, the underlying cushion 830, and the membrane 832 cooperate to define an external surface 882 that transitions from a relatively straight configuration to a curved configuration. This provides a relatively small offset for a more flexible spring component than the region R1.


As shown in FIG. 83, the base wall 828, the underlying cushion 830, and the membrane 832 cooperate to define an external surface 884 that curves outwards from the base wall 828. This provides a relatively large offset for an optimal spring component in the region R3, e.g., soft or flexible characteristics.


Thus, the cushion 810 may be designed to provide varying flexibilities around its perimeter which allows the cushion 810 to conform to a variety of facial shapes.



FIGS. 84-90 illustrate another embodiment of a cushion 910. The cushion 910 includes a base wall 928, an underlying support cushion 930, and a membrane 932. As illustrated, the underlying cushion 930 is preferably provided on lateral sides of the cushion 910 only, e.g., no underlying cushion at nasal bridge and chin regions (see FIG. 88).


As shown in FIG. 90, the base wall 928 includes a tapered portion 990 when compared to FIG. 89, which tapers towards the membrane 932. This arrangement may improve moldability.



FIG. 91 illustrates an alternative arrangement to the cushion 10 of FIG. 34A (arrangement of FIG. 34A shown in dashed lines). As illustrated, material has been removed from the side wall 28 and the space or gap 34 has been reduced with respect to the arrangement of FIG. 34A. This arrangement of FIG. 91 increases displacement with respect to the previous displacement of FIG. 34A. The increased displacement is achieved by the changed geometry in the side wall 28. It is noted that the gap 34 may be variable or constant around the cushion perimeter.



FIG. 92 illustrates an alternative arrangement to the cushion 10 of FIG. 34A (arrangement of FIG. 34A shown in dashed lines). As illustrated, some material has been removed from the side wall 28 and the space or gap 34 has been reduced with respect to the arrangement of FIG. 34A. This arrangement of FIG. 92 increases displacement with respect to the previous displacement of FIG. 34A. The increased displacement is achieved by the changed geometry in the side wall 28. This arrangement may require the cross-section of the base wall 28 to be thickened to add stiffness around the cushion perimeter or locally. Stiffening may be achieved by local ribs where required.



FIG. 93 illustrates an alternative arrangement to the cushion 10 shown in FIG. 15. As illustrated, the keyhole-shaped cutout (for receiving the patient's nasal bridge region) may be larger as the mask size reduces. For example, the cutout is larger for an extra small size mask than a large size mask.


It is noted that the cross-section design of the cushion at specific areas of the patient's face (e.g., FIGS. 23-29) may be in the specific area or any area around the cushion perimeter. That is, the cross-section design should not be limited to the specified area. Also, the cross-section shown in FIGS. 91 and 92 may be employed at any point around the cushion perimeter.


While the invention has been described in connection with what are presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the invention. Also, the various embodiments described above may be implemented in conjunction with other embodiments, e.g., aspects of one embodiment may be combined with aspects of another embodiment to realize yet other embodiments. In addition, while the invention has particular application to patients who suffer from OSA, it is to be appreciated that patients who suffer from other illnesses (e.g., congestive heart failure, diabetes, morbid obesity, stroke, barriatric surgery, etc.) can derive benefit from the above teachings. Moreover, the above teachings have applicability with patients and non-patients alike in non-medical applications.

Claims
  • 1. A cushion for a patient interface that delivers breathable gas to a patient, the cushion including a nasal bridge region, a pair of cheek regions, and a chin region, the pair of cheek regions including a pair of side of nose regions, a pair of upper cheek regions, and a pair of lower cheek regions, the cushion comprising: a non-face contacting portion including a base wall; anda face-contacting portion including a membrane connected to the base wall, the membrane having a thickness and including a nasal bridge region, a pair of side of nose regions, a pair of upper cheek regions, a pair of lower cheek regions and a chin region adapted to form a continuous seal, respectively, on a nasal bridge region, a pair of side of nose regions, a pair of upper cheek regions, a pair of lower cheek regions and a chin region of a patient's face,wherein an apex of a membrane curvature in the nasal bridge region of the cushion has a height in a direction towards the patient's face when the cushion is worn that is higher than or level with a height of an apex of a membrane curvature in adjacent portions of the pair of cheek regions of the cushion to, in use, accommodate different patient nose-bridge heights,wherein the membrane includes an external surface that forms a widest point of the cushion, and the base wall is internally offset with respect to the widest point such that, in use, when a frame force is applied to the cushion the face-contacting portion is configured to resiliently move relative to the non-face contacting portion with increased displacement thereby enhancing comfort to the patient, andwherein the chin region of the cushion is relatively flexible as compared to the lower cheek region of the cushion.
  • 2. The cushion according to claim 1, wherein, in at least the nasal bridge region and the chin region of the cushion, the cushion has a single-walled construction formed by the membrane.
  • 3. The cushion according to claim 1, wherein the nasal bridge region of the cushion has relatively high flexibility to conform to a variety of facial shapes, and the side of nose region of the cushion is relatively stiff to provide lateral stability to the cushion to facilitate constant contact of the membrane with the patient's face.
  • 4. The cushion according to claim 1, wherein the cushion has only a single-walled construction formed by the membrane in at least the nasal bridge region, the chin region and the pair of lower cheek regions of the cushion.
  • 5. The cushion according to claim 1, wherein an exterior surface of the membrane in the chin region extends from one lower cheek region to the other lower cheek region and forms a concave shape adapted to engage the patient's chin region.
  • 6. The cushion according to claim 1, wherein an inner edge of the membrane defines an aperture that is configured to receive the patient's nose and mouth, and wherein an apex of the aperture in the nasal bridge region of the cushion has a rounded notch.
  • 7. The cushion according to claim 1, wherein the apex of the membrane curvature in the nasal bridge region is disposed along a centerline of the cushion.
  • 8. The cushion according to claim 1, wherein the base wall is adapted to be permanently connected to a frame of a patient interface.
  • 9. The cushion according to claim 1, wherein the base wall is adapted to be removably connected to a frame of a patient interface.
  • 10. The cushion according to claim 1, the cushion further comprising a spring configuration that determines displacement of the cushion when a force is applied to the cushion by a frame.
  • 11. The cushion according to claim 10, wherein the spring configuration is provided in the nasal bridge region of the cushion.
  • 12. The cushion according to claim 10, wherein the spring configuration is provided in the pair of side of nose regions of the cushion.
  • 13. The cushion according to claim 1, wherein the thickness of the membrane in at least one of the nasal bridge region, the pair of side of nose regions, the pair of upper cheek regions, the pair of lower cheek regions and the chin region is different than the thickness in at least one other region.
  • 14. The cushion according to claim 13, wherein the thickness of membrane in the nasal bridge region is less than the thickness of the membrane in the pair of upper cheek regions.
  • 15. The cushion according to claim 13, wherein the thickness of the membrane in the nasal bridge region is less than the thickness of the membrane in the pair of lower cheek regions.
  • 16. The cushion according to claim 1, wherein the membrane in the nasal bridge region is configured to invert, in use, to accommodate patients having a range of nasal bridge profiles.
  • 17. The cushion according to claim 16, wherein an exterior surface of the membrane in the nasal bridge region forms an elongated ridge having sloping sides that meet to form an elongated crest, wherein the elongated ridge is structured to invert its configuration upon engagement with the patient's nasal bridge region, andwherein a leading edge of the elongated ridge is adapted to roll as the elongated ridge inverts its configuration.
  • 18. The cushion according to claim 1, wherein the cushion has only a single-walled construction formed by the membrane in at least the nasal bridge region, the chin region and the pair of lower cheek regions of the cushion, wherein an exterior surface of the membrane in the chin region extends from one lower cheek region to the other lower cheek region and forms a concave shape adapted to engage the patient's chin region,wherein an inner edge of the membrane defines an aperture that is configured to receive the patient's nose and mouth, and an apex of the aperture in the nasal bridge region of the cushion has a rounded notch,wherein the apex of the membrane curvature in the nasal bridge region is disposed along a centerline of the cushion, andwherein the thickness of the membrane in at least one of the nasal bridge region, the pair of side of nose regions, the pair of upper cheek regions, the pair of lower cheek regions and the chin region is different than the thickness in at least one other region.
  • 19. The cushion according to claim 18, the cushion further comprising a spring configuration that determines displacement of the cushion when a force is applied to the cushion by a frame, wherein the spring configuration is provided in the nasal bridge region of the cushion.
  • 20. A cushion for a patient interface that delivers breathable gas to a patient, the cushion including a nasal bridge region, a pair of cheek regions, and a chin region, the pair of cheek regions including a pair of side of nose regions, a pair of upper cheek regions, and a pair of lower cheek regions, the cushion comprising: a non-face contacting portion including a base wall; anda face-contacting portion including a membrane connected to the base wall, the membrane having a thickness and including a nasal bridge region, a pair of side of nose regions, a pair of upper cheek regions, a pair of lower cheek regions and a chin region adapted to form a continuous seal, respectively, on a nasal bridge region, a pair of side of nose regions, a pair of upper cheek regions, a pair of lower cheek regions and a chin region of a patient's face,wherein an apex of a membrane curvature in the nasal bridge region of the cushion has a height in a direction towards the patient's face when the cushion is worn that is higher than or level with a height of an apex of a membrane curvature in adjacent portions of the pair of cheek regions of the cushion to, in use, accommodate different patient nose-bridge heights, wherein the membrane includes an external surface that forms a widest point of the cushion, and the base wall is internally offset with respect to the widest point such that, in use, when a frame force is applied to the cushion the face-contacting portion is configured to resiliently move relative to the non-face contacting portion with increased displacement thereby enhancing comfort to the patient, andwherein, in at least the nasal bridge region and the chin region of the cushion, the cushion has a single-walled construction formed by the membrane.
  • 21. The cushion according to claim 20, wherein the nasal bridge region of the cushion has relatively high flexibility to conform to a variety of facial shapes, and the side of nose region of the cushion is relatively stiff to provide lateral stability to the cushion to facilitate constant contact of the membrane with the patient's face.
  • 22. The cushion according to claim 20, wherein the apex of the membrane curvature in the nasal bridge region is disposed along a centerline of the cushion.
  • 23. The cushion according to claim 20, the cushion further comprising a spring configuration that determines displacement of the cushion when a force is applied to the cushion by a frame.
  • 24. The cushion according to claim 20, wherein the membrane in the nasal bridge region is configured to invert, in use, to accommodate patients having a range of nasal bridge profiles.
  • 25. The cushion according to claim 20, wherein the cushion also has a single-walled construction formed by the membrane in the pair of lower cheek regions of the cushion, wherein the chin region of the cushion is relatively flexible as compared to the lower cheek region of the cushion,wherein an exterior surface of the membrane in the chin region extends from one lower cheek region to the other lower cheek region and forms a concave shape adapted to engage the patient's chin region,wherein an inner edge of the membrane defines an aperture that is configured to receive the patient's nose and mouth, and an apex of the aperture in the nasal bridge region of the cushion has a rounded notch,wherein the apex of the membrane curvature in the nasal bridge region is disposed along a centerline of the cushion, andwherein the thickness of the membrane in at least one of the nasal bridge region, the pair of side of nose regions, the pair of upper cheek regions, the pair of lower cheek regions and the chin region is different than the thickness in at least one other region.
CROSS-REFERENCE TO APPLICATIONS

This application is a continuation of U.S. Ser. No. 15/077,515, filed Mar. 22, 2016, allowed, which is a continuation of U.S. Ser. No. 14/136,163, filed Dec. 20, 2013, now U.S. Pat. No. 9,295,800, which is a continuation of U.S. Ser. No. 13/688,931, filed Nov. 29, 2012, now U.S. Pat. No. 8,613,281, which is a continuation of U.S. Ser. No. 13/537,876, filed Jun. 29, 2012, now U.S. Pat. No. 8,485,192, which is a continuation of U.S. Ser. No. 11/793,981, filed Jun. 25, 2007, now U.S. Pat. No. 8,220,459, which is the US national phase of international application PCT/AU2006/000032, filed 12 Jan. 2006, which designated the U.S. and claims the benefit of U.S. Provisional Application Nos. 60/643,130, filed Jan. 12, 2005, and 60/724,303, filed Oct. 7, 2005, each of which is hereby incorporated herein by reference in its entirety.

US Referenced Citations (635)
Number Name Date Kind
443191 Illing Dec 1890 A
781516 Guthrie, Jr. Jan 1905 A
812706 Warbasse Feb 1906 A
1081745 Johnston Dec 1913 A
1125542 Humphries Jan 1915 A
1192186 Greene Jul 1916 A
1229050 Donald Jun 1917 A
1282527 Bidonde Oct 1918 A
1362766 McGargill Dec 1920 A
1445010 Feinberg Feb 1923 A
1610793 Kaufman Dec 1926 A
1632449 McKesson Jun 1927 A
1653572 Jackson Dec 1927 A
1710160 Gibbs Apr 1929 A
1926027 Biggs Apr 1929 A
1873160 Sturtevant Aug 1932 A
2011733 Shindel Aug 1935 A
2104016 Biggs Jan 1938 A
2123353 Catt Jul 1938 A
2130555 Malcom Sep 1938 A
2133699 Heidbrink Oct 1938 A
2166164 Lehmberg Jul 1939 A
2248477 Lombard Jul 1941 A
2254854 O'Connell Sep 1941 A
2317608 Heidbrink Apr 1943 A
2353643 Bulbulian Jul 1944 A
2371965 Lehmberg Mar 1945 A
2376871 Fink May 1945 A
2415846 Randall Feb 1947 A
2428451 Emerson Oct 1947 A
2433565 Korman Dec 1947 A
2438058 Kincheloe Mar 1948 A
2578621 Yant Dec 1951 A
2625155 Engelder Jan 1953 A
2641253 Engelder Jun 1953 A
2875759 Galleher Dec 1954 A
2706983 Matheson et al. Apr 1955 A
2749910 Faulconer, Jr. Jun 1956 A
RE24193 Emerson Aug 1956 E
2837090 Bloom et al. Jun 1958 A
2875757 Galleher, Jr. Mar 1959 A
2881444 Fresh et al. Apr 1959 A
2882895 Galeazzi Apr 1959 A
2902033 Galleher, Jr. Sep 1959 A
2931356 Schwarz Apr 1960 A
D188084 Garelick May 1960 S
2939458 Lundquist Jun 1960 A
3013556 Galleher, Jr. Dec 1961 A
3182659 Blount May 1965 A
3189027 Webb et al. Jul 1965 A
3238943 Holley Mar 1966 A
3315674 Bloom et al. Apr 1967 A
3330273 Bennett Jul 1967 A
3330274 Bennett Jul 1967 A
3362420 Blackburn et al. Jan 1968 A
3363833 Laerdal Jan 1968 A
3545436 Holloway Dec 1970 A
3556122 Laerdal Jan 1971 A
3580051 Blevins May 1971 A
3670726 Mahon et al. Mar 1972 A
3682171 Dali et al. Aug 1972 A
3700000 Hesse Oct 1972 A
3720235 Schrock Mar 1973 A
3739774 Gregory Jun 1973 A
3754552 King Aug 1973 A
3796216 Schwarz Mar 1974 A
3799164 Rollins Mar 1974 A
D231803 Huddy Jun 1974 S
3861385 Carden Jan 1975 A
3902486 Guichard Sep 1975 A
3905361 Hewson et al. Sep 1975 A
3910261 Ragsdale et al. Oct 1975 A
3938614 Ahs Feb 1976 A
3972321 Proctor Aug 1976 A
4006744 Steer Feb 1977 A
4062357 Laerdal Dec 1977 A
4069516 Watkins, Jr. Jan 1978 A
4077404 Elam Mar 1978 A
D250131 Lewis et al. Oct 1978 S
4142527 Garcia Mar 1979 A
4153051 Shippert May 1979 A
4156426 Gold May 1979 A
4167185 Lewis Sep 1979 A
4226234 Gunderson Oct 1980 A
4239038 Holmes Dec 1980 A
4245632 Houston Jan 1981 A
4248218 Fischer Feb 1981 A
4263908 Mizerak Apr 1981 A
4264743 Maruyama et al. Apr 1981 A
4265239 Fischer, Jr. et al. May 1981 A
4267845 Robertson, Jr. et al. May 1981 A
4273124 Zimmerman Jun 1981 A
D262322 Mizerak Dec 1981 S
4304229 Curtin Dec 1981 A
4312359 Olson Jan 1982 A
4328797 Rollins et al. May 1982 A
4347205 Stewart Aug 1982 A
4354488 Bartos Oct 1982 A
4367735 Dali Jan 1983 A
4367816 Wilkes Jan 1983 A
4402316 Gadberry Sep 1983 A
4406283 Bir Sep 1983 A
4412537 Tiger Nov 1983 A
4414973 Matheson et al. Nov 1983 A
4422456 Teip Dec 1983 A
4449526 Elam May 1984 A
4455675 Bose et al. Jun 1984 A
4467799 Steinberg Aug 1984 A
4493614 Chu et al. Jan 1985 A
4522639 Ansite et al. Jun 1985 A
4548200 Wapner Oct 1985 A
4549542 Chein Nov 1985 A
4558710 Eichler Dec 1985 A
4572323 Randall Feb 1986 A
4587967 Chu et al. May 1986 A
4601465 Roy Jul 1986 A
D285496 Berman Sep 1986 S
4616647 McCreadie Oct 1986 A
4617637 Chu et al. Nov 1986 A
4622964 Flynn Nov 1986 A
4630604 Montesi Dec 1986 A
4641645 Tayebi Feb 1987 A
4641647 Behan Feb 1987 A
D289238 Arthur, Jr. Apr 1987 S
4655213 Rapoport et al. Apr 1987 A
4660555 Payton Apr 1987 A
4665570 Davis May 1987 A
4671267 Stout Jun 1987 A
4671271 Bishop et al. Jun 1987 A
4676241 Webb et al. Jun 1987 A
4677975 Edgar et al. Jul 1987 A
4677977 Wilcox Jul 1987 A
4699139 Marshall et al. Oct 1987 A
4706664 Snook et al. Nov 1987 A
4711636 Bierman Dec 1987 A
4713844 Westgate Dec 1987 A
H397 Stark Jan 1988 H
D293613 Wingler Jan 1988 S
4739755 White et al. Apr 1988 A
4753233 Grimes Jun 1988 A
4767411 Edmunds Aug 1988 A
4770169 Schmoegner et al. Sep 1988 A
4774941 Cook Oct 1988 A
4774946 Ackerman et al. Nov 1988 A
4782832 Trimble et al. Nov 1988 A
4790829 Bowden et al. Dec 1988 A
4799477 Lewis Jan 1989 A
4802857 Laughlin Feb 1989 A
4803981 Vickery Feb 1989 A
4809692 Nowacki et al. Mar 1989 A
4811730 Milano Mar 1989 A
4819629 Jonson Apr 1989 A
4821713 Bauman Apr 1989 A
4830138 Palmaer et al. May 1989 A
4838878 Kalt et al. Jun 1989 A
4841953 Dodrill Jun 1989 A
4848334 Bellm Jul 1989 A
4848366 Aita et al. Jul 1989 A
4899740 Napolitano Feb 1990 A
4905683 Cronjaeger Mar 1990 A
4907584 McGinnis Mar 1990 A
4910806 Baker et al. Mar 1990 A
4914957 Dougherty Apr 1990 A
4915105 Lee Apr 1990 A
4919128 Kopala et al. Apr 1990 A
4919654 Kalt Apr 1990 A
4938210 Shene Jul 1990 A
4938212 Snook et al. Jul 1990 A
4941476 Fisher Jul 1990 A
4944310 Sullivan Jul 1990 A
4945907 Tayebi Aug 1990 A
4947860 Fisher Aug 1990 A
D310431 Bellm Sep 1990 S
4960121 Nelson et al. Oct 1990 A
4966590 Kalt Oct 1990 A
4969880 Zamierowski Nov 1990 A
4971051 Toffolon Nov 1990 A
4976698 Stokley Dec 1990 A
4986269 Hakkinen Jan 1991 A
4989596 Macris et al. Feb 1991 A
4989599 Carter Feb 1991 A
4996983 Amrhein Mar 1991 A
5000173 Zalkin et al. Mar 1991 A
5003633 Itoh Apr 1991 A
5005568 Loescher et al. Apr 1991 A
5005571 Dietz Apr 1991 A
5020163 Aileo et al. Jun 1991 A
5022900 Bar-Yona et al. Jun 1991 A
5023955 Murphy, II et al. Jun 1991 A
5025805 Nutter Jun 1991 A
5038772 Kolbe et al. Aug 1991 A
5038776 Harrison et al. Aug 1991 A
5042473 Lewis Aug 1991 A
5042478 Kopala et al. Aug 1991 A
5046200 Feder Sep 1991 A
5046491 Derrick Sep 1991 A
5062421 Burns et al. Nov 1991 A
5063922 Hakkinen Nov 1991 A
5069205 Urso Dec 1991 A
5074297 Venegas Dec 1991 A
5080092 Tenna Jan 1992 A
D323908 Holister et al. Feb 1992 S
5109839 Blasdell et al. May 1992 A
5109840 Daleiden May 1992 A
5113857 Dickerman et al. May 1992 A
5117818 Palfy Jun 1992 A
5121745 Israel Jun 1992 A
5121746 Sikora Jun 1992 A
5127397 Kohnke Jul 1992 A
5133347 Huennebeck Jul 1992 A
5137017 Salter Aug 1992 A
5138722 Urella et al. Aug 1992 A
5140980 Haughey et al. Aug 1992 A
5140982 Bauman Aug 1992 A
5159938 Laughlin Nov 1992 A
5178138 Walstrom et al. Jan 1993 A
5181506 Tardiff, Jr. et al. Jan 1993 A
D333015 Farmer et al. Feb 1993 S
5188101 Tumolo Feb 1993 A
D334633 Rudolph Apr 1993 S
5199424 Sullivan Apr 1993 A
5207665 Davis et al. May 1993 A
5220699 Farris Jun 1993 A
5222478 Scarberry et al. Jun 1993 A
5231983 Matson et al. Aug 1993 A
5233978 Callaway Aug 1993 A
5243709 Sheehan et al. Sep 1993 A
5243971 Sullivan et al. Sep 1993 A
5245995 Sullivan et al. Sep 1993 A
5261893 Zamierowski Nov 1993 A
5263939 Wortrich Nov 1993 A
5265592 Beaussant Nov 1993 A
5265595 Rudolph Nov 1993 A
5267557 Her-Mou Dec 1993 A
5269296 Landis Dec 1993 A
5271391 Graves Dec 1993 A
5279289 Kirk Jan 1994 A
5280784 Kohler Jan 1994 A
5299448 Maryyanek Apr 1994 A
5299579 Gedeon et al. Apr 1994 A
5299599 Farmer et al. Apr 1994 A
5304146 Johnson et al. Apr 1994 A
5311862 Blasdell et al. May 1994 A
5322057 Raabe et al. Jun 1994 A
D349586 Handke Aug 1994 S
5335656 Bowe et al. Aug 1994 A
5343878 Scarberry et al. Sep 1994 A
5349949 Schegerin Sep 1994 A
5353789 Schlobohm Oct 1994 A
5355878 Griffiths et al. Oct 1994 A
5355893 Mick et al. Oct 1994 A
5357951 Ratner Oct 1994 A
5364367 Banks et al. Nov 1994 A
5372130 Stem et al. Dec 1994 A
5372388 Gargiulo Dec 1994 A
5372389 Tam et al. Dec 1994 A
5372390 Conway et al. Dec 1994 A
5372391 Bast et al. Dec 1994 A
5375593 Press Dec 1994 A
5385141 Granatiero Jan 1995 A
5388571 Roberts et al. Feb 1995 A
5391248 Brain Feb 1995 A
5394568 Brostrom et al. Mar 1995 A
5396885 Nelson Mar 1995 A
5398676 Press et al. Mar 1995 A
5400776 Bartholomew Mar 1995 A
5404871 Goodman et al. Apr 1995 A
5419318 Tayebi May 1995 A
5425359 Liou Jun 1995 A
5429126 Bracken Jul 1995 A
5429683 Le Mitouard Jul 1995 A
5431158 Tirotta Jul 1995 A
5437267 Weinstein et al. Aug 1995 A
5438981 Starr et al. Aug 1995 A
5441046 Starr et al. Aug 1995 A
D362061 McGinnis et al. Sep 1995 S
5462528 Roewer Oct 1995 A
5477852 Landis et al. Dec 1995 A
5479920 Piper et al. Jan 1996 A
5488948 Dubruille et al. Feb 1996 A
5492116 Scarberry et al. Feb 1996 A
5501214 Sabo Mar 1996 A
5503147 Bertheau Apr 1996 A
5509404 Lloyd et al. Apr 1996 A
5509409 Weatherholt Apr 1996 A
5513634 Jackson May 1996 A
5513635 Bedi May 1996 A
5517986 Starr et al. May 1996 A
5526806 Sansoni Jun 1996 A
5533506 Wood Jul 1996 A
5538000 Rudolph Jul 1996 A
5538001 Bridges Jul 1996 A
5540223 Starr et al. Jul 1996 A
5542128 Lomas Aug 1996 A
5546936 Virag et al. Aug 1996 A
5558090 James Sep 1996 A
RE35339 Rapoport Oct 1996 E
5560354 Berthon-Jones et al. Oct 1996 A
5570682 Johnson Nov 1996 A
5570684 Behr Nov 1996 A
5570689 Starr et al. Nov 1996 A
D377089 Starr et al. Dec 1996 S
5592938 Scarberry et al. Jan 1997 A
5608647 Rubsamen et al. Mar 1997 A
5623923 Bertheau et al. Apr 1997 A
5642726 Owens et al. Jul 1997 A
5642730 Baran Jul 1997 A
5647355 Starr et al. Jul 1997 A
5647356 Barnett et al. Jul 1997 A
5647357 Barnett et al. Jul 1997 A
5649532 Griffiths Jul 1997 A
5649533 Oren Jul 1997 A
5653228 Byrd Aug 1997 A
5655520 Howe et al. Aug 1997 A
5655527 Scarberry et al. Aug 1997 A
5657493 Ferrero et al. Aug 1997 A
5657752 Landis et al. Aug 1997 A
5660171 Kimm et al. Aug 1997 A
5662101 Ogden et al. Sep 1997 A
5666946 Langenback Sep 1997 A
5676133 Hickle et al. Oct 1997 A
5682881 Winthrop et al. Nov 1997 A
5685296 Zdrojkowski Nov 1997 A
5687715 Landis et al. Nov 1997 A
D389238 Kirk, III et al. Jan 1998 S
5704345 Berthon-Jones et al. Jan 1998 A
5715814 Ebers Feb 1998 A
5724965 Handke et al. Mar 1998 A
5735272 Dillon et al. Apr 1998 A
5740799 Nielson Apr 1998 A
5746201 Kidd May 1998 A
5752509 Lachmann et al. May 1998 A
5752511 Simmons et al. May 1998 A
5778872 Fukunaga et al. Jul 1998 A
5782774 Shmulewitz Jul 1998 A
5794615 Estes Aug 1998 A
5794619 Edeiman et al. Aug 1998 A
5807341 Heim Sep 1998 A
5813423 Kirchgeorg Sep 1998 A
5832918 Pantino Nov 1998 A
5842469 Rapp et al. Dec 1998 A
5884624 Barnett et al. Mar 1999 A
5887587 Groenke Mar 1999 A
5906203 Klockseth et al. May 1999 A
5918598 Belfer et al. Jul 1999 A
5921239 McCall et al. Jul 1999 A
D412745 Scheu Aug 1999 S
5935136 Hulse et al. Aug 1999 A
5937445 Ravo et al. Aug 1999 A
5937851 Serowski et al. Aug 1999 A
5954049 Foley et al. Sep 1999 A
5970975 Estes et al. Oct 1999 A
5975079 Hellings et al. Nov 1999 A
6003511 Fukunaga et al. Dec 1999 A
6006748 Hollis Dec 1999 A
6016804 Gleason et al. Jan 2000 A
6019101 Cotner et al. Jan 2000 A
6026811 Settle Feb 2000 A
6039044 Sullivan Mar 2000 A
6044844 Kwok et al. Apr 2000 A
6082360 Rudolph et al. Jul 2000 A
6086118 McNaughton et al. Jul 2000 A
6095996 Steer et al. Aug 2000 A
6098205 Schwartz et al. Aug 2000 A
6102040 Tayebi et al. Aug 2000 A
6109263 Feuchtgruber Aug 2000 A
6112746 Kwok et al. Sep 2000 A
6119693 Kwok et al. Sep 2000 A
6119694 Correa et al. Sep 2000 A
6123071 Berthon-Jones et al. Sep 2000 A
6123082 Berthon-Jones Sep 2000 A
6135109 Blasdell et al. Oct 2000 A
6139787 Harrison Oct 2000 A
6152137 Schwartz et al. Nov 2000 A
6155253 Gamberini Dec 2000 A
6192886 Rudolph Feb 2001 B1
6193914 Harrison Feb 2001 B1
6196223 Belfer et al. Mar 2001 B1
6211263 Cinelli et al. Apr 2001 B1
6213125 Reese et al. Apr 2001 B1
6231548 Bassett May 2001 B1
6241930 Harrison Jun 2001 B1
6258066 Urich Jul 2001 B1
6295366 Baller et al. Sep 2001 B1
6328031 Tischer et al. Dec 2001 B1
6328038 Kessler et al. Dec 2001 B1
6340024 Brookman et al. Jan 2002 B1
6341606 Bordewick et al. Jan 2002 B1
6345618 Hayek Feb 2002 B1
6347631 Hansen et al. Feb 2002 B1
6357440 Hansen et al. Mar 2002 B1
6357441 Kwok et al. Mar 2002 B1
6358279 Tahi et al. Mar 2002 B1
6371110 Peterson et al. Apr 2002 B1
6374826 Gunaratnam et al. Apr 2002 B1
6397847 Scarberry et al. Jun 2002 B1
6412487 Gunaratnam et al. Jul 2002 B1
6412488 Barnett et al. Jul 2002 B1
6412593 Jones Jul 2002 B1
6419660 Russo Jul 2002 B1
6422238 Lithgow Jul 2002 B1
6423036 Van Huzen Jul 2002 B1
6425395 Brewer et al. Jul 2002 B1
6427694 Hecker et al. Aug 2002 B1
6431172 Bordewick Aug 2002 B1
6434796 Speirs Aug 2002 B1
6439234 Curti et al. Aug 2002 B1
6448303 Paul Sep 2002 B1
6467482 Boussignac Oct 2002 B1
6467483 Kopacko et al. Oct 2002 B1
6470887 Martinez Oct 2002 B1
6478026 Wood Nov 2002 B1
6482178 Andrews et al. Nov 2002 B1
6491034 Gunaratnam et al. Dec 2002 B1
6513526 Kwok et al. Feb 2003 B2
6530373 Patron et al. Mar 2003 B1
6532961 Kwok et al. Mar 2003 B1
6536435 Fecteau et al. Mar 2003 B1
6561188 Ellis May 2003 B1
6561190 Kwok et al. May 2003 B1
6561192 Palmer May 2003 B2
6561193 Noble May 2003 B1
6571798 Thornton Jun 2003 B1
6579267 Lynch et al. Jun 2003 B2
6581601 Ziaee Jun 2003 B2
6581602 Kwok et al. Jul 2003 B2
6584975 Taylor Jul 2003 B1
6595214 Hecker et al. Jul 2003 B1
6595215 Wood Jul 2003 B2
6607516 Cinelli et al. Aug 2003 B2
6626177 Ziaee Sep 2003 B1
6627289 Dilnik et al. Sep 2003 B1
6631718 Lovell Oct 2003 B1
6634358 Kwok et al. Oct 2003 B2
6637434 Noble Oct 2003 B2
6644315 Ziaee Nov 2003 B2
6651663 Barnett et al. Nov 2003 B2
D484237 Lang et al. Dec 2003 S
6655385 Curti et al. Dec 2003 B1
6663600 Bierman et al. Dec 2003 B2
6669712 Cardoso Dec 2003 B1
D485905 Moore et al. Jan 2004 S
6679257 Robertson et al. Jan 2004 B1
6679265 Strickland et al. Jan 2004 B2
6691708 Kwok et al. Feb 2004 B2
6701926 Olsen et al. Mar 2004 B2
6701927 Kwok et al. Mar 2004 B2
6710099 Cinelli et al. Mar 2004 B2
6729333 Barnett et al. May 2004 B2
6766800 Chu et al. Jul 2004 B2
6766817 da Silva Jul 2004 B2
6772760 Frater et al. Aug 2004 B2
6776162 Wood Aug 2004 B2
6776163 Dougill et al. Aug 2004 B2
6789543 Cannon Sep 2004 B2
6796308 Gunaratnam et al. Sep 2004 B2
6805117 Ho et al. Oct 2004 B1
6807967 Wood Oct 2004 B2
6817362 Gelinas et al. Nov 2004 B2
6820617 Robertson et al. Nov 2004 B2
6823865 Drew et al. Nov 2004 B2
6823869 Raje et al. Nov 2004 B2
6834650 Fini Dec 2004 B1
6851429 Bishop Feb 2005 B2
6860269 Kwok et al. Mar 2005 B2
6860270 Sniadich Mar 2005 B2
6871649 Kwok et al. Mar 2005 B2
6895965 Scarberry et al. May 2005 B2
6907882 Ging et al. Jun 2005 B2
6914091 Donald et al. Jul 2005 B2
6918404 Dias da Silva Jul 2005 B2
6926004 Schumacher Aug 2005 B2
6938620 Payne, Jr. Sep 2005 B2
6959710 Barnett et al. Nov 2005 B2
6968844 Liland Nov 2005 B2
6972003 Bierman et al. Dec 2005 B2
6986352 Frater et al. Jan 2006 B2
6997177 Wood Feb 2006 B2
7000614 Lang et al. Feb 2006 B2
7007696 Palkon et al. Mar 2006 B2
7011090 Drew et al. Mar 2006 B2
7018362 Bierman et al. Mar 2006 B2
7040321 Goebel May 2006 B2
7052127 Harrison May 2006 B2
7066586 da Silva Jun 2006 B2
7069932 Eaton et al. Jul 2006 B2
7076282 Munro et al. Jul 2006 B2
7076822 Pearce Jul 2006 B2
7080645 Genger et al. Jul 2006 B2
7093599 Chen Aug 2006 B2
7100610 Biener et al. Sep 2006 B2
7101359 Kline et al. Sep 2006 B2
7107989 Frater et al. Sep 2006 B2
7114497 Aylsworth et al. Oct 2006 B2
7146976 McKown Dec 2006 B2
7152599 Thomas Dec 2006 B2
7152601 Barakat et al. Dec 2006 B2
7178525 Matula, Jr. et al. Feb 2007 B2
7191781 Wood Mar 2007 B2
7207328 Altemus Apr 2007 B1
7210481 Lovell et al. May 2007 B1
7237551 Ho et al. Jul 2007 B2
7243723 Surjaatmadja Jul 2007 B2
D550836 Chandran et al. Sep 2007 S
D552733 Criscuolo et al. Oct 2007 S
7285255 Kadlec et al. Oct 2007 B2
7302950 Berthon-Jones et al. Dec 2007 B2
7308895 Wixey et al. Dec 2007 B2
7318437 Gunaratnam et al. Jan 2008 B2
7318439 Raje et al. Jan 2008 B2
7341060 Ging et al. Mar 2008 B2
7353826 Sleeper et al. Apr 2008 B2
7441618 Sorg Oct 2008 B2
7470256 Lampropoulos et al. Dec 2008 B2
7481220 Meyer et al. Jan 2009 B2
7520869 Lampropoulos et al. Apr 2009 B2
7523754 Lithgow et al. Apr 2009 B2
7562658 Madaus et al. Jul 2009 B2
7614401 Thompson Nov 2009 B2
7621274 Sprinkle et al. Nov 2009 B2
7624735 Ho et al. Dec 2009 B2
7631644 Ho et al. Dec 2009 B2
7640934 Zollinger et al. Jan 2010 B2
7658189 Davidson et al. Feb 2010 B2
7699808 Marrs et al. Apr 2010 B2
7703457 Barnett et al. Apr 2010 B2
7708017 Davidson May 2010 B2
7743767 Ging et al. Jun 2010 B2
7775209 Biener et al. Aug 2010 B2
7779832 Ho Aug 2010 B1
7798144 Kwok et al. Sep 2010 B2
7814911 Bordewick et al. Oct 2010 B2
7827990 Melidis et al. Nov 2010 B1
7856980 Lang et al. Dec 2010 B2
7900631 Persson Mar 2011 B2
7931024 Ho et al. Apr 2011 B2
7942148 Davidson May 2011 B2
7958893 Lithgow et al. Jun 2011 B2
7971590 Frater et al. Jul 2011 B2
7997267 Ging et al. Aug 2011 B2
8042541 Amarasinghe et al. Oct 2011 B2
8042542 Ging et al. Oct 2011 B2
8051850 Kwok et al. Nov 2011 B2
8091553 Bordewick et al. Jan 2012 B2
8136524 Ging et al. Mar 2012 B2
8136525 Lubke et al. Mar 2012 B2
8186352 Gunaratnam et al. May 2012 B2
8210180 Gunaratnam Jul 2012 B2
8220459 Davidson et al. Jul 2012 B2
8297283 Hitchcock et al. Oct 2012 B2
8397728 D'Souza Mar 2013 B2
20010020474 Hecker et al. Sep 2001 A1
20020020416 Namey Feb 2002 A1
20020029780 Frater et al. Mar 2002 A1
20020046755 Devoss Apr 2002 A1
20020066452 Kessler et al. Jun 2002 A1
20020069872 Gradon et al. Jun 2002 A1
20020124849 Billette de Villemeur Sep 2002 A1
20020143296 Russo Oct 2002 A1
20020157673 Kessler et al. Oct 2002 A1
20020174868 Kwok et al. Nov 2002 A1
20030019495 Palkon et al. Jan 2003 A1
20030089373 Gradon et al. May 2003 A1
20030145859 Bohn et al. Aug 2003 A1
20030168063 Gambone et al. Sep 2003 A1
20030196655 Ging et al. Oct 2003 A1
20030196656 Moore et al. Oct 2003 A1
20030196657 Ging et al. Oct 2003 A1
20030196658 Ging et al. Oct 2003 A1
20040106891 Langan et al. Jun 2004 A1
20040111104 Schein et al. Jun 2004 A1
20040112384 Lithgow et al. Jun 2004 A1
20040112385 Drew et al. Jun 2004 A1
20040118406 Lithgow et al. Jun 2004 A1
20040127856 Johnson Jul 2004 A1
20040144386 Frater et al. Jul 2004 A1
20040182398 Sprinkle et al. Sep 2004 A1
20040211428 Jones Oct 2004 A1
20040221850 Ging et al. Nov 2004 A1
20040226566 Gunaratnam et al. Nov 2004 A1
20050005940 Gunaratnum et al. Jan 2005 A1
20050051171 Booth Mar 2005 A1
20050051176 Riggins Mar 2005 A1
20050056286 Huddart et al. Mar 2005 A1
20050061326 Payne, Jr. Mar 2005 A1
20050150495 Rittner et al. Jul 2005 A1
20050155604 Ging et al. Jul 2005 A1
20050211252 Lang et al. Sep 2005 A1
20050241644 Gunaratnam et al. Nov 2005 A1
20050257792 Wixey et al. Nov 2005 A1
20060060200 Ho et al. Mar 2006 A1
20060118117 Berthon-Jones Jun 2006 A1
20060124131 Chandran et al. Jun 2006 A1
20060137690 Gunaratnam et al. Jun 2006 A1
20060174887 Chandran et al. Aug 2006 A1
20060207597 Wright Sep 2006 A1
20060207599 Busch et al. Sep 2006 A1
20060213520 Frater et al. Sep 2006 A1
20070125384 Zollinger et al. Jun 2007 A1
20070221226 Hansen Sep 2007 A1
20070272249 Chandran et al. Nov 2007 A1
20070282272 Bannon et al. Dec 2007 A1
20080004573 Kaufmann et al. Jan 2008 A1
20080006277 Worboys et al. Jan 2008 A1
20080047560 Veliss et al. Feb 2008 A1
20080060649 Veliss et al. Mar 2008 A1
20080065022 Kyvik et al. Mar 2008 A1
20080110464 Davidson et al. May 2008 A1
20080110469 Weinberg May 2008 A1
20080178886 Lieberman et al. Jul 2008 A1
20080200880 Kyvik et al. Aug 2008 A1
20080257354 Davidson et al. Oct 2008 A1
20080302365 Cohen Dec 2008 A1
20090044808 Guney et al. Feb 2009 A1
20090139526 Melidis et al. Jun 2009 A1
20090173343 Omura et al. Jul 2009 A1
20090217929 Kwok et al. Sep 2009 A1
20090223518 Kwok et al. Sep 2009 A1
20100000534 Kooij et al. Jan 2010 A1
20100000543 Berthon-Jones Jan 2010 A1
20100018534 Veliss et al. Jan 2010 A1
20100089401 Lang et al. Apr 2010 A1
20100132717 Davidson et al. Jun 2010 A1
20100192955 Biener et al. Aug 2010 A1
20100282265 Melidis et al. Nov 2010 A1
20100319700 Ng et al. Dec 2010 A1
20110056497 Scheiner et al. Mar 2011 A1
20110220110 Frater et al. Sep 2011 A1
20110220114 Lithgow et al. Sep 2011 A1
20120174928 Raje et al. Jul 2012 A1
20120266886 Davidson et al. Oct 2012 A1
20130037033 Hitchcock et al. Feb 2013 A1
20130086796 Davidson et al. Apr 2013 A1
20140144449 Davidson et al. May 2014 A1
20160213874 Davidson et al. Jul 2016 A1
Foreign Referenced Citations (140)
Number Date Country
681645 Dec 1994 AU
199651130 Oct 1996 AU
2005100738 Nov 2005 AU
1735439 Feb 2006 CN
101862496 Oct 2010 CN
185 017 May 1907 DE
30 11 900 Oct 1980 DE
146 688 Jan 1981 DE
31 49 449 Oct 1982 DE
37 19 009 Dec 1988 DE
39 27 038 Feb 1991 DE
42 33 448 Apr 1993 DE
196 03 949 Aug 1997 DE
297 23 101 Jul 1998 DE
197 03 526 Aug 1998 DE
199 44 242 Mar 2001 DE
100 02 571 Jul 2001 DE
199 62 515 Jul 2001 DE
102 13 905 Oct 2002 DE
102 26 587 Jan 2004 DE
10 2004 055 433 Nov 2004 DE
103 31 837 Jan 2005 DE
20 2004 018 108 Feb 2005 DE
103 38 169 Mar 2005 DE
0 288 937 Nov 1988 EP
0 334 555 Sep 1989 EP
0 427 474 May 1991 EP
0 466 960 Jan 1992 EP
0 303 090 Apr 1992 EP
0 658 356 Jun 1995 EP
0 747 078 Dec 1996 EP
0 776 679 Jun 1997 EP
0 853 962 Jul 1998 EP
1 099 452 May 2001 EP
1 118 346 Jul 2001 EP
1 205 205 May 2002 EP
1 258 266 Nov 2002 EP
1 306 098 May 2003 EP
1 334 742 Aug 2003 EP
1 356 841 Oct 2003 EP
1 356 843 Oct 2003 EP
1 360 971 Nov 2003 EP
1 481 702 Dec 2004 EP
2 471 566 Jul 2012 EP
2 471 567 Jul 2012 EP
2 720 280 Dec 1995 FR
2 823 122 Oct 2002 FR
532 214 Jan 1941 GB
649 689 Jan 1951 GB
848215 Sep 1960 GB
2 176 404 Dec 1986 GB
2 368 533 May 2002 GB
2 385 533 May 2003 GB
S51-142793 Nov 1976 JP
H03-007173 Jan 1991 JP
H11-000397 Jan 1999 JP
H11-104256 Apr 1999 JP
2000-515784 Nov 2000 JP
2003-512902 Apr 2003 JP
2003-175106 Jun 2003 JP
2003-535657 Dec 2003 JP
2004-000570 Jan 2004 JP
2005-337371 Dec 2005 JP
2005-537906 Dec 2005 JP
2006-505373 Feb 2006 JP
3802872 Jul 2006 JP
WO 1982003548 Oct 1982 WO
WO 1987001950 Apr 1987 WO
WO 1992020392 Nov 1992 WO
WO 1992020395 Nov 1992 WO
WO 1996028207 Sep 1996 WO
WO 1998003145 Jan 1998 WO
WO 1998004310 Feb 1998 WO
WO 1998012965 Apr 1998 WO
WO 1998023305 Jun 1998 WO
WO 1998034665 Aug 1998 WO
WO 1998048878 Nov 1998 WO
WO 1999016327 Apr 1999 WO
WO 1999025410 May 1999 WO
WO 1999043375 Sep 1999 WO
WO 1999061088 Dec 1999 WO
WO 2000020072 Apr 2000 WO
WO 2000038772 Jul 2000 WO
WO 2000050121 Aug 2000 WO
WO 2000069521 Nov 2000 WO
WO 2000072905 Dec 2000 WO
WO 2000074758 Dec 2000 WO
WO 2000076568 Dec 2000 WO
WO 2000078384 Dec 2000 WO
WO 2001062326 Aug 2001 WO
WO 2001095965 Dec 2001 WO
WO 2001097892 Dec 2001 WO
WO 2001097893 Dec 2001 WO
WO 2002038221 May 2002 WO
WO 2002045784 Jun 2002 WO
WO 2003090827 Nov 2003 WO
WO 2003105921 Dec 2003 WO
WO 2004007010 Jan 2004 WO
WO 2004022146 Mar 2004 WO
WO 2004022147 Mar 2004 WO
WO 2004041342 May 2004 WO
WO 2004073778 Sep 2004 WO
WO 2004078230 Sep 2004 WO
WO 2004096332 Nov 2004 WO
WO 2005018523 Mar 2005 WO
WO 2005021075 Mar 2005 WO
WO 2005028010 Mar 2005 WO
WO 2005053781 Jun 2005 WO
WO 2005063328 Jul 2005 WO
WO 2005086943 Sep 2005 WO
WO 2005094928 Oct 2005 WO
WO 2005099801 Oct 2005 WO
WO 2005110220 Nov 2005 WO
WO 2005118040 Dec 2005 WO
WO 2005123166 Dec 2005 WO
WO 2006014630 Feb 2006 WO
WO 2006052653 May 2006 WO
WO 2006069345 Jun 2006 WO
WO 2006069415 Jul 2006 WO
WO 2006074513 Jul 2006 WO
WO 2006074514 Jul 2006 WO
WO 2006074516 Jul 2006 WO
WO 2006099658 Sep 2006 WO
WO 2006102707 Oct 2006 WO
WO 2006130903 Dec 2006 WO
WO 2007009182 Jan 2007 WO
WO 2007041751 Apr 2007 WO
WO 2007041786 Apr 2007 WO
WO 2007045008 Apr 2007 WO
WO 2007048174 May 2007 WO
WO 2007053878 May 2007 WO
WO 2007143772 Dec 2007 WO
WO 2007145534 Dec 2007 WO
WO 2008011682 Jan 2008 WO
WO 2008011683 Jan 2008 WO
WO 2008040050 Apr 2008 WO
WO 2008070929 Jun 2008 WO
WO 2009108994 Sep 2009 WO
WO 2009109004 Sep 2009 WO
WO 2010028425 Mar 2010 WO
Non-Patent Literature Citations (252)
Entry
JP Office Action and English translation thereof dated Sep. 17, 2019 in corresponding JP Application P2018-031815.
AU Examination Report No. 2 for standard patent application dated Dec. 10, 2019 in corresponding AU Application 2018267671.
Report on the Reexamination Prior To Trial and English translation thereof mailed Sep. 30, 2021 in corresponding JP Application 2019-080949 (3 pages).
Notice of Reasons for Rejection and English translation thereof dated Oct. 11, 2021 in corresponding JP Application P2020-154569 (13 pages).
Second Office Action, and English translation thereof dated Mar. 5, 2021 in corresponding CN Application 201810652985.4 (9 pages).
Final Rejection and English translation thereof dated Mar. 15, 2021 in corresponding JP Application P2019-080949 (5 pages).
First Examination Report dated Feb. 4, 2021 in corresponding NZ Application 772374 (2 pages).
CN Office Action and English translation thereof dated Jun. 28, 2020 in corresponding CN Application 201810652985.4.
JP Office Action and English translation thereof dated Jun. 15, 2020 in corresponding JP Application P2019-080949.
JP Notice of Allowance dated May 25, 2020 in corresponding JP Application 2018-031815.
EP Search Report dated May 28, 2020 in corresponding EP Application 19208580.1.
Non-final Office Action issued in related U.S. Appl. No. 12/081,696, dated Sep. 12, 2013, including Form PTO-892 listing US 2008/0110464, US 2009/0078267, US 2010/0108072, U.S. Pat. No. 8,220,459, U.S. Pat. No. 8,485,192, U.S. Pat. No. 8,522,784, and US 2009/0139526.
Communication pursuant to Article 94(3) EPC issued in a corresponding European Patent Application No. 12 154 923.2-1662 dated Jun. 21, 2013.
First Examination Report issued in a corresponding New Zealand Patent Application No. 612757 dated Jul. 11, 2013.
“Introducing The Sullivan Bubble Mask System—Series 3,” USPTO to assume before Applicant's filing date.
“The Sullivan Mask System,” USPTO to assume before Applicant's filing date.
“There are a lot of Noses Out There . . . ,” dated 1995.
“The Sullivan—APD 2 Nasal CPAP System,” USPTO to assume before Applicant's filing date.
“ResMed Origins,” USPTO to assume before Applicant's filing date.
Sullivan Comfort—Bi-level System (Operating Manual), dated 2000.
“Modular Mask Components,” www.resmed.com/products/standard.htm, captured Dec. 15, 2000.
“Nasal Cushions,” www.resmed.com/cushions/cushions.htm, captured Jan. 4, 1997.
“Mask Frames,” www.resmed.com/maskframes/mask.htm, captured Jan. 4, 1997.
Sullivan Series 1 Cushions (3 pages (Photo-1 to Photo-3)), USPTO to assume before Applicant's filing date.
Sullivan Series 2 Cushions (5 pages (Photo-1 to Photo-5)), USPTO to assume before Applicant's filing date.
Sullivan Series 3 Cushions (5 pages (Photo-1 to Photo-5)), USPTO to assume before Applicant's filing date.
Sullivan Mask Fitting Kit (6 pages (Photo-1 to Photo-6)), USPTO to assume before Applicant's filing date.
ResCare—Sullivan Mask Components Case (7 pages (Photo-1 to Photo-7)), USPTO to assume before Applicant's filing date.
Large Ultra Mirage Mask—Standard Cushion (as shown in photos (14)), representative of cushion aperture dimensions of Full-Face masks, USPTO to assume before Applicant's filing date.
Large Ultra Mirage Mask—Shallow Cushion (as shown in photos (14)), representative of cushion aperture dimensions of Full-Face masks, USPTO to assume before Applicant's filing date.
Medium Ultra Mirage Mask—Standard Cushion (as shown in photos (14)), representative of cushion aperture dimensions of Full-Face masks, USPTO to assume before Applicant's filing date.
Medium Ultra Mirage Mask—Shallow Cushion (as shown in photos (14)), representative of cushion aperture dimensions of Full-Face masks, USPTO to assume before Applicant's filing date.
Small Ultra Mirage Mask—Standard Cushion (as shown in photos (18)), representative of cushion aperture dimensions of Full-Face masks, USPTO to assume before Applicant's filing date.
Small Ultra Mirage Mask—Shallow Cushion (as shown in photos (14)), representative of cushion aperture dimensions of Full-Face masks, USPTO to assume before Applicant's filing date.
Table 1—cushion aperture dimensions of Ultra Mirage Full-Face Masks (Large, Medium and Small sizes (Standard and Shallow versions)), USPTO to assume before Applicant's filing date.
Office Action dated Jan. 15, 2013 issued in corresponding JP Patent Application No. 2011-185789 (and English translation thereof).
Office Action issued in a related U.S. Appl. No. 12/081,696, dated Feb. 28, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/537,876, dated Feb. 27, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/676,736, dated Mar. 26, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/676,869, dated Mar. 26, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/676,925, dated Mar. 26, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/687,680, dated Mar. 26, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/688,575, dated Apr. 3, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/688,619, dated Apr. 2, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/688,890, dated Apr. 3, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/688,875, dated Apr. 2, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/689,211, dated Apr. 1, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/689,094, dated Mar. 29, 2013.
Office Action issued in a corresponding U.S. Appl. No. 13/689,210, dated Apr. 8, 2013.
Office Action issued in a related Chinese Appln. No. 200810109270.0 (dated Mar. 28, 2013) with English Translation thereof.
U.S. Appl. No. 13/745,077, filed Jan. 22, 2013.
U.S. Appl. No. 13/747,701, filed Jan. 23, 2013.
U.S. Appl. No. 13/747,772, filed Jan. 23, 2013.
U.S. Appl. No. 13/834,189, filed Mar. 15, 2013.
U.S. Appl. No. 13/676,736, filed Nov. 14, 2012.
U.S. Appl. No. 13/676,869, filed Nov. 14, 2012.
U.S. Appl. No. 13/676,925, filed Nov. 14, 2012.
U.S. Appl. No. 13/688,575, filed Nov. 29, 2012.
U.S. Appl. No. 13/687,680, filed Nov. 28, 2012.
U.S. Appl. No. 13/688,619, filed Nov. 29, 2012.
U.S. Appl. No. 13/688,890, filed Nov. 29, 2012.
U.S. Appl. No. 13/688,875, filed Nov. 29, 2012.
U.S. Appl. No. 13/689,211, filed Nov. 29, 2012.
U.S. Appl. No. 13/689,094, filed Nov. 29, 2012.
U.S. Appl. No. 13/689,210, filed Nov. 29, 2012.
“Ear Loop Face Mask”, before Applicant's filing date.
Adam J. Singer MD et al. “The Cyanoacrylate Topical Skin Adhesives,” American Journal of Emergency Medicine, vol. 26, 2008, pp. 490-496.
Australian Appln. No. 2005253641—Examiner's First Report, dated Apr. 20, 2010.
Australian Appln. No. 2005253641—Examiner's Report, dated Aug. 18, 2011.
Australian Appln. No. 2006206040—Examination Report, dated Jun. 27, 2012.
Chinese Appln. No. 200580020203.6—Office Action (w/English translation), dated Jun. 1, 2010.
Chinese Appln. No. 200580020203.6—Office Action (w/English translation), dated Jul. 6, 2011.
Chinese Appln. No. 200580020203.6—Office Action (w/English translation), dated Dec. 23, 2011.
Chinese Appln. No. 200580020203.6—Office Action (w/English translation), dated Apr. 18, 2012.
Chinese Appln. No. 200680002169.4—Third Office Action (w/English translation), dated Nov. 11, 2010.
Chinese Appln. No. 200680002169.4—Office Action (w/English translation), dated Mar. 23, 2010.
Chinese Appln. No. 200810109270.0—Office Action (w/English translation), dated Oct. 19, 2011.
Chinese Appln. No. 200810109270.0—Office Action (w/English translation), dated Jun. 27, 2012.
Chinese Appln. No. 201010000226.3—Office Action (w/English translation), dated Apr. 26, 2012.
ComfortLite™, Respironics, http://comfortlite.respironics.com, before Applicant's filing date.
ComfortLite™ 2, Respironics, http://comfortlite2.respironics.com, before Applicant's filing date.
European Appln. No. EP 01944732.5—Office Action, dated Nov. 27, 2009.
European Appln. No. EP 03793493.2—Supplementary Search Report, dated Dec. 2, 2009.
European Appln. No. EP 03793493.2—Office Action, dated Mar. 18, 2011.
European Appln. No. EP 03810331.3—Supplementary Search Report, dated Dec. 18, 2009.
European Appln. No. EP 04802133.1—Supplementary Search Report, dated Sep. 8, 2009.
European Appln. No. EP 04802133.1—Office Action, dated Dec. 22, 2009.
European Appln. No. EP 05746824.1—Supplementary Search Report, dated Dec. 17, 2009.
European Appln. No. EP 05749447.8—Supplementary Search Report, dated Dec. 8, 2009.
European Appln. No. EP 06704287.9—Supplementary Search Report, dated Oct. 6, 2009.
European Appln. No. EP 06704287.9—Office Action, dated Jul. 18, 2011.
European Appln. No. EP 07784697.0—Search Report, dated Jul. 27, 2009.
European Appln. No. EP 07845378.4—Search Report, dated Dec. 1, 2009.
European Appln. No. EP 08154854.7—Extended Search Report, dated Nov. 27, 2008.
European Appln. No. EP 08154854.7—Examination Report, dated Jul. 1, 2011.
European Appln. No. EP 08161249.1—Extended Search Report, dated Mar. 19, 2009.
European Appln .No. EP 09003544.5—Search Report, dated Jun. 2, 2009.
European Appln. No. EP 09161984.1—Extended Search Report, dated Sep. 3, 2009.
European Appln. No. EP 11174401.7—Search Report, dated Oct. 20, 2011.
European Appln. No. EP 11174407.4—Extended Search Report, dated Oct. 20, 2011.
European Appln. No. EP 12154923.2—Extended Search Report, dated Jun. 1, 2012.
European Appln. No. EP 12154926.6—Extended Search Report, dated Jun. 6, 2012.
Fisher and Paykel Col.—Product Family—http://www.fphcare.com/osa/products.asp/, before Applicant's filing date.
Hans Rudolph, Inc.—Mask Products—http://www.rudolphkc.com/products.php?category=MASKS, before Applicant's filing date.
“If You Hate CPAP! You Need CPAP Pro®,” www.cpappro.com, before Applicant's filing date.
Japanese Appln. No. 2005-337371—Reasons for Rejection (w/English translation), dated Feb. 22, 2011.
Japanese Appln. No. 2005-337371—Final Office Action (w/English translation), dated Jan. 31, 2012.
Japanese Appln. No. 2007-515732—Office Action (w/English translation), dated Aug. 24, 2010.
Japanese Appln. No. 2007-515732—Office Action (w/English translation), dated Aug. 16, 2011.
Japanese Appln. No. 2007-515732—Office Action (w/English translation), dated Jun. 12, 2012.
Japanese Appln. No. 2007-550636—Office Action (w/English translation), dated Mar. 18, 2011.
Japanese Appln. No. 2007-550636—Office Action (w/English translation), dated Mar. 21, 2012.
Japanese Appln. No. 2007-550636—Notice of Allowance (w/English translation), dated Jul. 10, 2012.
Japanese Appln. No. 2009-140433—Office Action (w/English translation), dated Aug. 20, 2011.
Japanese Appln. No. 2009-140433—Notice of Allowance, dated Sep. 4, 2012.
Japanese Appln. No. 2010-195597—Office Action (w/English translation), dated Jun. 12, 2012.
Japanese Appln. No. 2010-214485—Office Action (w/English translation), dated Jun. 12, 2012.
Japanese Appln. No. 2011-038110—Office Action (w/English translation), dated Aug. 14, 2012.
JP 11-000397A Machine Translation, provided by the Japanese Patent Office, Jan. 6, 2009, full document.
Joel W. Beam, “Tissue Adhesives for Simple Traumatic Lacerations,” Journal of Athletic Training, 2008, vol. 43, No. 2, pp. 222-224.
Laurent Brochard, “Pressure Support Ventilation,” Chapter 9, Part IV—Conventional Methods of Ventilator Support, pp. 239-257, 1994.
McPherson et al., “Respiratory Therapy Equipment,” Chapter 8, Third Edition, Introduction to Ventilators, pp. 230-253, 1985.
Merriam-Webster Online Dictionary definition of moveable from the 14th century, before Applicant's filing date.
New Zealand Appln. No. 597552—Examination Report, dated Jan. 19, 2012.
New Zealand Appln. No. 587820—Examination Report, dated Sep. 13, 2010.
New Zealand Appln. No. 587344—Examination Report, dated Jan. 19, 2012.
New Zealand Appln. No. 587344—Examination Report, dated Aug. 3, 2012.
New Zealand Appln. No. 539836—Examination Report, dated Aug. 25, 2005.
New Zealand Appln. No. 2003275762—Examiner's Report No. 3, dated Nov. 18, 2009.
PCT/AU2003/001163—International Search Report, dated Nov. 4, 2003.
PCT/AU2003/001471—International Search Report, dated Feb. 12, 2004.
PCT/AU2004/001832—International Search Report, dated Mar. 24, 2005.
PCT/AU2004/001832—International Preliminary Report on Patentability, dated Jul. 3, 2006.
PCT/AU2005/000803—International Search Report, dated Jun. 30, 2005.
PCT/AU2005/000850—International Search Report, dated Aug. 12, 2005.
PCT/AU2005/000850—International Preliminary Report on Patentability, dated Dec. 20, 2006.
PCT/AU2006/000032—International Preliminary Report on Patentability, dated Jul. 17, 2007.
PCT/AU2006/000032—International Search Report, dated May 15, 2006.
PCT/AU2006/000770—International Search Report, dated Aug. 3, 2006.
PCT/AU2007/001051—International Search Report, dated Nov. 5, 2007.
PCT/AU2007/001052—International Search Report, dated Oct. 9, 2007.
PCT/AU2007/001456—International Search Report, dated Dec. 12, 2007.
PCT/AU2007/001936—International Search Report, dated Mar. 4, 2008.
PCT/AU2009/000240—International Search Report, dated May 21, 2009.
PCT/AU2009/000262—International Search Report, dated Jun. 9, 2009.
PCT/AU2009/001144—International Search Report, dated Dec. 8, 2009.
ResMed Co.—Mask Products—http://resmed.com/portal/site/ResMedUS/index.jsp? , before Applicant's filing date.
Respironics Co.—Mask Family—http://masksfamily.respironics.com/, before Applicant's filing date.
Respironics Contour mask with Comfort Flap (released 1993).
Respironics Contour Deluxe mask (released 2000).
Respironics ComfortFull FF mask (released 2003).
SNAPP Nasal Interface, Tiara Medical Systems, Inc.—http://tiaramed.com/asp_shops/shopdisplayproducts.asp?id=109&cat=SNAPP%2A+Nasal+Interface, before Applicant's filing date.
Subbu Venkatraman et al., “Review Skin Adhesives and Skin Adhesion 1. Transdermal Drug Delivery Systems,” Biomaterials, vol. 19, 1998, pp. 1119-1136.
Tiara Medical Systems, Inc., “Advantage HUSH Nasal Mask,”?, Tiara Medical Systems, Inc., before Applicant's filing date.
Unsolicited email from Elson Silva, PhD, dated Mar. 28, 2008, “Requesting IDS of U.S. Pat. No. 6,766,817 for patents on fluids moving on porosity by Unsaturated Hydraulic Flow,” (email provided in both HTML and plain text format).
U.S. Appl. No. 60/424,686, filed Nov. 8, 2002 (expired).
U.S. Appl. No. 60/483,622, filed Jul. 1, 2003 (expired).
U.S. Appl. No. 60/533,214, filed Dec. 31, 2003 (expired).
U.S. Appl. No. 60/634,802, filed Dec. 10, 2004 (expired).
U.S. Appl. No. 60/643,121, filed Jan. 12, 2005 (expired).
U.S. Appl. No. 60/645,672, filed Jan. 21, 2005 (expired).
U.S. Appl. No. 60/795,615, filed Apr. 28, 2006 (expired).
U.S. Appl. No. 60/833,841, filed Jul. 28, 2006 (expired).
U.S. Appl. No. 60/835,442, filed Aug. 4, 2006 (expired).
U.S. Appl. No. 60/852,649, filed Oct. 19, 2006 (expired).
U.S. Appl. No. 60/874,968, filed Dec. 15, 2006 (expired).
U.S. Appl. No. 60/907,856, filed Apr. 19, 2007 (expired).
U.S. Appl. No. 60/924,241, filed May 4, 2007 (expired).
U.S. Appl. No. 60/929,393, filed Jun. 25, 2007 (expired).
U.S. Appl. No. 60/935,179, filed Jul. 30, 2007 (expired).
U.S. Appl. No. 60/935,336, filed Aug. 8, 2007 (expired).
U.S. Appl. No. 60/996,160, filed Nov. 5, 2007 (expired).
U.S. Appl. No. 61/006,409, filed Jan. 11, 2008 (expired).
U.S. Appl. No. 61/064,818, filed Mar. 28, 2008 (expired).
U.S. Appl. No. 61/071,512, filed May 2, 2008 (expired).
U.S. Appl. No. 61/213,326, filed May 29, 2009 (expired).
U.S. Appl. No. 61/222,711, filed Jul. 2, 2009 (expired).
U.S. Appl. No. 61/263,175, filed Nov. 20, 2009 (expired).
U.S. Appl. No. 61/272,162, filed Aug. 25, 2009 (expired).
U.S. Appl. No. 61/272,250, filed Sep. 4, 2009 (expired).
Webster's New World Dictionary, Third College Edition 1988, definition for engaged and flexible, before Applicant's filing date.
Webster's Third New International Dictionary, 1993, Dictionary definition for adjustable, bendable, and mild steel, before Applicant's filing date.
Decision of Rejection issued in corresponding Japanese Application No. 2011-185789 dated Oct. 8, 2013 with English translation thereof.
Communication Pursuant to Article 94(3) EPC dated Oct. 23, 2015 in a related European Application No. 11 174 401.7-1662 (5 pages).
Subpoena for Court Hearing (1 page) issued Oct. 22, 2015 in the opposition proceeding for a corresponding Chinese Application No. 200680002169.4, along with Arguments of the Defendant (5 pages) and Third-Party (3 pages), and English translations thereof (1 page, 6 pages, and 4 pages, respectively).
Decision of Rejection dated Sep. 14, 2015 in a corresponding Japanese Application No. 2014-023455 (3 pages) and an English translation thereof (3 pages).
Patent Examination Report No. 1 dated Aug. 5, 2015, in a corresponding Australian Application No. 2014202899 (3 pages).
Communication issued in a corresponding European Application No. 12154926.5 (9 pages), dated Jul. 10, 2015, including Reply Brief from Opponent and English translation thereof (6 pages).
Decision of Rejection dated Jun. 25, 2015 in a corresponding Chinese Application No. 201110339739.1 (5 pages) and English translation thereof (8 pages).
First Examination Report dated Feb. 10, 2015 issued in corresponding New Zealand Application No. 701102 (2 pages).
Decision of Reexamination dated Jan. 23, 2015 issued in related Chinese Application No. 200810109270.0 with English translation (29 pages).
First Office Action issued in corresponding Chinese Application No. 201110339739.1 dated Dec. 30, 2013 with English-language translation.
Notification of the Acceptance of a Request for the Invalidation of a Patent Right, including the Request for the Invalidation of a Patent Right, issued in corresponding Chinese Application No. 200680002169.4 dated Nov. 29, 2013, with English-language translation.
Notice of Allowance issued in corresponding Japanese Application No. 2013-084905 dated Feb. 17, 2014.
Extended European Search Report dated Feb. 7, 2014 in corresponding European Patent Application No. 13 17 8116.
Extended European Search Report dated Feb. 28, 2014 in corresponding European Patent Application No. 13 17 8114.
Extended European Search Report dated Mar. 4, 2014 in corresponding European Patent Application No. 13 17 8113.
Extended European Search Report dated Mar. 4, 2014 in corresponding European Patent Application No. 13 17 8112.
Extended European Search Report dated Mar. 10, 2014 in corresponding European Patent Application No. 13 17 8111.
Notice of Opposition dated Jul. 15, 2014 in corresponding European Patent Application No. 2 471 567 with English translation.
Notification of Reexamination dated Aug. 13, 2014 in Chinese Application No. 200810109270.0 with English translation (16 pages).
Notification of the Second Office Action dated Sep. 2, 2014 in corresponding Chinese Application No. 201110339739.1 with English translation thereof.
Further Examination Report dated Nov. 7, 2014 issued in corresponding New Zealand Application No. 612757 (2 pages).
Office Action dated Nov. 24, 2014 issued in corresponding European Application No. 13 178 111.4 (5 pages).
Notice of Reasons for Rejection dated Jan. 5, 2015 issued in corresponding Japanese Application No. 2014-023455 with English translation (6 pages).
Notification of the Third Office Action dated Dec. 31, 2014 issued in corresponding Chinese Application No. 201110339739.1 with English translation (9 pages).
First Office Action dated Mar. 7, 2016 in a corresponding Japanese Patent Application No. 2015-77497 (7 pages) and English translation thereof (6 pages).
First Office Action dated Jan. 28, 2016, in a corresponding Chinese Application No. 201410475657.3 (11 pages), and an English translation thereof (13 pages).
A First Amended Notice of Opposition to Grant of Patent (Section 21) (2 pages) and Statement of Case (24 pages) filed Feb. 28, 2017, in a corresponding New Zealand Application No. 701102.
A Decision of Rejection dated Mar. 27, 2017, in a corresponding Chinese Application No. 2014104756573 (10 pages), and an English translation thereof (12 pages).
CN Office Action and English translation thereof dated Aug. 14, 2019 in corresponding CN Application 201710061203.5 (8 pages).
Rule 94(3) Communication dated Nov. 30, 2016 in a corresponding European Application No. 13 178 112.2 (5 pages).
Rule 94(3) Communication dated Dec. 1, 2016 in a corresponding European Application No. 13 178 113.0 (5 pages).
Decision of Rejection dated Nov. 21, 2016 in a corresponding Japanese Application No. 2015-077497 (4 pages), and an English translation thereof (7 pages).
Decision of Rejection dated Oct. 10, 2016 in a corresponding Chinese Application No. 201110339739.1 (8 pages) and an English translation thereof (11 pages).
Fourth Office Action dated May 3, 2016 in a corresponding Chinese Application No. 201110339739.1 (5 pages) and an English translation thereof (9 pages).
Communication Pursuant to Article 94(3) EPC dated Jun. 14, 2016, in a related European Application No. 11 174 401.7-1662 (4 pages).
Patent Examination Report No. 2 dated Mar. 1, 2016 in a corresponding Australian Patent Application No. 2014202899 (2 pages).
First Examination Report dated Jul. 26, 2016, in a corresponding New Zealand Application No. 721231 (2 pages).
Second Office Action dated Sep. 5, 2016, in a corresponding Japanese Application No. 2014-23455 (4 pages), and an English translation thereof (6 pages).
Second Office Action dated Oct. 8, 2016 in a corresponding Chinese Application No. 201410475657.3 (9 pages), and an English translation thereof (12 pages).
Notice of Opposition filed Nov. 28, 2016 in a corresponding New Zealand Application No. 701102 (3 pages).
A Reply Brief filed Jan. 13, 2017 by Air Liquide Medical Systems in an opposition proceeding against a corresponding European Patent No. 2,471 567 (formerly European Patent Application No. 12 15 4926.5) (3 pages), and an English translation thereof (3 pages).
Invitation Pursuant to Rule 137(4) and Article 94(3) dated Jan. 1, 2017, in a corresponding European Application No. 13 17 8114.8 (3 pages).
A Communication Pursuant to Article 94(3) EPC dated Feb. 15, 2017, in a related European Application No. 11 174 401.7 (4 pages).
Brief Communication from the European Patent Office dated Jan. 19, 2017, forwarding the Reply of Air Liquide Medical Systems filed in an Opposition Proceeding against corresponding EP Patent 2 471 567, and an English translation thereof (7 pages).
Interlocutory Decision in Opposition Proceedings (Art. 101(3)(a) and 106(2) EPC) issued Mar. 1, 2017, in an Opposition Proceeding against corresponding EP Patent 2 471 567 (16 pages), including Auxiliary Request 1 (67 pages), and Provision of the Minutes in Accordance with Rule 124(4) EPC (11 pages).
Non-Final Office Action dated Mar. 24, 2017, in a related U.S. Appl. No. 14/523,216 (61 pages).
A Communication Pursuant to Article 94(3) EPC dated Jul. 17, 2017, in a corresponding European Patent Application No. 13 178 116.3 (9 pages).
Examination Report No. 1 for Standard Patent Application dated Aug. 11, 2017 in a corresponding Australian Application No. 2016204360 (6 pages).
A Communication Issued Pursuant to Article 94(3) EPC, dated Aug. 21, 2017, issued in a corresponding European Application No. 13 178 112.2 (4 pages).
An Examination Decision of the Patent Reexamination Board dated Mar. 22, 2018, in a corresponding Chinese Patent Application No. 201110339739.1 (8 pages), and an English translation thereof (11 pages).
A Notification of Reexamination dated Apr. 8, 2018, in a corresponding Chinese Patent Application No. 2018040201346100 (6 pages), and an English translation thereof (7 pages).
A Notice of Opposition, transmittal letter, and Application for Extension of Time submitted Jul. 23, 2018, and Jul. 24, 2018 letter from the New Zealand Intellectual Property Office granting the Extension, all in a corresponding New Zealand Patent Application No. 721231 (5 pages).
An Examination Report No. 2 issued in corresponding Australian Application No. 2016204360 dated Aug. 2, 2018, (6 pages).
A Notification of Reexamination issued in corresponding Chinese Application No. 2014104756573 dated Sep. 20, 2018, with English translation, (18 pages).
A Letter filed by AJ Park on behalf of Fisher & Paykel Healthcare Limited in corresponding New Zealand Application Nos. 721231 on Nov. 23, 2018 (1 page).
An Amended Notice of Opposition to Grant of Patent (Section 21) issued in corresponding New Zealand Application No. 721231 dated Nov. 26, 2018 (tracked) (2 pages).
An Amended Notice of Opposition to Grant of Patent (Section 21) issued in corresponding New Zealand Application No. 721231 dated Nov. 26, 2018 (clean) (2 pages).
A Statement of Case filed by Fisher & Paykel Healthcare Limited in corresponding New Zealand Opposition No. 721231 dated Nov. 26, 2018 (15 pages).
A First Office Action issued in corresponding Chinese Application No. 2017100612035 dated Dec. 3, 2018, with English translation, (17 pages).
A Deadline for Counterstatement issued in corresponding New Zealand Application No. 721231 dated Jan. 9, 2019, (2 pages), Amended Notice of Opposition and Statement of Case were previously submitted.
Decision of Reexamination in corresponding Chinese Application No. 201410475657.3 dated Jan. 23, 2019, with English translation (33 pages).
A First Office Action issued in corresponding Japanese Application No. 2018-031815 dated Jan. 10, 2019, with English translation, (7 pages).
EP Search Report dated Jun. 3, 2019 in related EP application 18189933.7.
AU Exam Report No. 1 dated Mar. 28, 2019 in corresponding AU application 2018267671.
Further Examination Report dated Aug. 12, 2019 in NZ application 739443 (2 pages).
First Examination Report dated Aug. 12, 2019 in NZ application 755863 (2 pages).
Notice of Reasons for Rejection and English translation thereof dated Feb. 28, 2022 in corresponding JP Application 2019-080949 (7 pages).
Notification of the First Office Action and English translation thereof dated Apr. 6, 2022 in corresponding CN Application 202010398322.1 (18 pages).
Notice of Reasons for Rejection and English translation thereof dated May 30, 2022 in corresponding JP Application 2020-154569 (10 pages).
Communication pursuant to Article 94(3) EPC dated Jun. 27, 2022 in corresponding EP Application 19208580.1 (8 pages).
Related Publications (1)
Number Date Country
20200009343 A1 Jan 2020 US
Provisional Applications (2)
Number Date Country
60643130 Jan 2005 US
60724303 Oct 2005 US
Continuations (5)
Number Date Country
Parent 15077515 Mar 2016 US
Child 16575427 US
Parent 14136163 Dec 2013 US
Child 15077515 US
Parent 13688931 Nov 2012 US
Child 14136163 US
Parent 13537876 Jun 2012 US
Child 13688931 US
Parent 11793981 US
Child 13537876 US